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1. Introduction
Society is facing serious challenges in 
diagnosing and treating complex diseases, 
such as cancer and inflammatory disease 
and complications from chronic diseases. 
In addition, there is a rapidly increasing 
need to fight antibiotic resistance. 
Advances in medical research and emer-
gence of new technologies and new mate-
rials are important to improve detection of, 
and provide novel and effective therapies 
for these diseases in healthcare. Improved 
knowledge of the underlining causes of 
disease and mechanistic insight into dis-
ease mechanisms drive development of 
novel molecular therapies. However, the 
therapeutic discovery and development 
process is currently most often inefficient 
and lacks predictive power and results in 
very high costs (>1 billion € per launched 
drug) and long duration (up to >15 years) 
of the drug development and regulatory 
processes. Further, clinical translation of 
Approaches to increase the efficiency in developing drugs and diagnostics 
tools, including new drug delivery and diagnostic technologies, are needed 
for improved diagnosis and treatment of major diseases and health problems 
such as cancer, inflammatory diseases, chronic wounds, and antibiotic resist-
ance. Development within several areas of research ranging from computa-
tional sciences, material sciences, bioengineering to biomedical sciences and 
bioimaging is needed to realize innovative drug development and diagnostic 
(DDD) approaches. Here, an overview of recent progresses within key areas 
that can provide customizable solutions to improve processes and the 
approaches taken within DDD is provided. Due to the broadness of the area, 
unfortunately all relevant aspects such as pharmacokinetics of bioactive mol-
ecules and delivery systems cannot be covered. Tailored approaches within (i) 
bioinformatics and computer-aided drug design, (ii) nanotechnology, (iii) novel 
materials and technologies for drug delivery and diagnostic systems, and (iv) 
disease models to predict safety and efficacy of medicines under development 
are focused on. Current developments and challenges ahead are discussed. 
The broad scope reflects the multidisciplinary nature of the field of DDD and 
aims to highlight the convergence of biological, pharmaceutical, and medical 
disciplines needed to meet the societal challenges of the 21st century.
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novel therapeutic approaches and drugs is hampered by sev-
eral challenges, including aspects regarding safety and efficacy, 
pharmacokinetics, and bioavailability, and can only be solved 
with systematic multidisciplinary approaches. The heteroge-
neous nature of many diseases, the complexity of genetic vari-
ability, and the need for personalized medicine pose additional 
challenges, but at the same time give great opportunities in 
realizing future therapies. Often, diagnostic and therapeutic 
approaches need to be combined and tailored to the patient, 
and the development process should be adapted accordingly. In 
Table 1, we summarize some of the biggest medical challenges 
of the 21st century.
In this review, we introduce recent developments and 
approaches within materials sciences and technology that 
address the needs that exist in the development of efficient 
therapies and sensitive diagnostic solutions (Figure 1). We also 
cover computational, engineered, and biological approaches 
as well as model systems that can provide customizable solu-
tions to improve the processes and approaches taken within 
DDD. We discuss the state of the art and provide a critical 
analysis of the problems in the respective fields, addressing 
the challenges, limitations, and possible solutions. The scope 
of the review is large to emphasize the need of interdiscipli-
nary approaches. The cross-disciplinary scope is also intended 
to familiarize the reader with the possibilities and limitations 
of other fields, to hopefully render crossover approaches more 
effective.
2. Computational Approaches in Molecular 
Design and Drug Discovery
2.1. Structural Bioinformatics and Computer-Aided Drug Design 
in Drug Development and Diagnostics
The study of individual molecules and collections of molecules, 
isolated and in the cellular or organismal context, is important 
for identifying synthetic and natural molecules in drug devel-
opment and diagnostic applications. Structural biology can 
define the biological complex, while structural bioinformatics 
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seeks to assimilate a wide range of information to make predic-
tions, when structural and functional details are incomplete.[1] 
Different computer-aided drug design techniques can utilize 
the available structural information from either known small-
molecule compounds (i.e., ligands) or the target macromol-
ecules, which usually are proteins. In the ideal case, structural 
and biological data from a panel of diverse ligands, as well as 
from the target protein and close homologs of the target pro-
vide a rich pool of information to exploit. In order to be able 
to efficiently employ the existing and ever-increasing molecular 
information for facilitating the design and discovery of novel 
drug candidates or diagnostic compounds, one also needs to be 
aware of the limitations and risks involved in using computa-
tional approaches.
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2.1.1. Macromolecular 3D Structures
Known 3D structures of proteins are available in the Protein 
Data Bank (PDB).[2] To solve protein structures experimentally, 
X-ray crystallography or nuclear magnetic resonance (NMR) 
spectroscopy give the highest resolution. However, lower res-
olution structural data from experimental techniques such as 
(cryo)electron microscopy (EM), small-angle X-ray scattering 
(SAXS), or fluorescence resonance energy transfer (FRET) can 
also be utilized to solve structural models with the help of com-
putational tools.[1] A single experimental structure is informa-
tive, but seldom sufficient, especially if it does not reflect a 
protein in complex with a ligand or an important conforma-
tional state. Structures with and without bound ligands, as 
well as mutational and functional data elucidating molecular 
interactions and activity states, would provide a more complete 
description of the dynamics taking place upon ligand binding, 
during reactions, and interactions with other molecules in the 
surroundings.
In reality, structural data from X-ray crystallography and 
NMR spectroscopy and especially from the lower resolution 
experimental techniques are rarely complete, and structural 
representatives of the protein of interest may not be forth-
coming despite intense efforts. Structural bioinformatics can 
Adv. Healthcare Mater. 2017, 6, 1700258
Table 1. Medical challenges of the 21st century.[16]
Disease Impact Challenges Need
Cancer - 14 million deaths in 2012, expected to 
increase to 24 million by 2035
- Tumor heterogeneity
- Therapy resistance
- Adverse side effects  
of novel compounds
- Predictive drug screening
- Targeted drug delivery
- Sensitive diagnostics
- Immunotherapies
- Personalized medicine  
(dose and drug combinations)
Chronic wounds - 2015: worldwide 50 million diabetes 
related chronic wounds and 10–15 
million amputations
- 2.4–4.5 million people affected by chronic 
lower extremity ulcers in the United 
States only
- Multiple genetic and environmental factors 
contribute to delayed healing
- Therapy selection often not evidence based
- Lack of efficacy evaluation of existing wound 
care products
- Deep understanding of the 
underlying pathophysiology
- Advanced therapy systems (bioactive 
wound dressing)
- Personalized medicine (selection 
of an appropriate therapy based on 
a systematic evaluation of patients 
and their wounds)
Inflammatory disorders Asthma
- 250 000 deaths annually
Allergies
- One tenth of the population suffers from 
drug allergies.
- 400 million people from rhinitis
- 250 million people from food allergies 
Autoimmune diseases
- Affect more than 5% of the population in 
Europe and North America
Chronic inflammation
- Over 1 million residents in the United 
States and 2.5 million in Europe are 
estimated to have inflammatory bowel 
disease (IBD).
- Treatments affecting inflammatory responses 
that do not compromise the host’s ability to 
fight infections
- Chronic disorders tend to require life-long 
medication.
- Disorders are usually multifactorial, and suc-
cessful treatments, thus, will vary in patients.
- Controlled dosage and specific 
targeting for prolonged treatments
- Immunotherapy and desensitizing 
therapies
- Efficient, but noninvasive 
diagnostics
- Specific diagnosis and further 
subclassification of disorders
- Development of drugs for specific 
disorders
Antibiotic resistance - 2014: WHO’s global antibacterial resis-
tance surveillance: antibiotic resistance 
risk treatment of common infections
- 2017: WHO’s list of antibiotic-resistant 
“priority pathogens”: a catalogue of 12 
families of bacteria that pose the greatest 
threat to human health
- Deaths caused by drug-resistant bacteria 
in the EU amount to 25 000 annually, 
costing society €1.5 billion
- Deaths caused by drug-resistant bacteria 
in 2050 could be as enormous as  
10 million per year
- Bacteria develop resistance mechanisms 
faster than new antibiotics are being 
developed.
- Bacteria can pass on genetic material to other 
bacteria to acquire drug resistance.
- Misuse of antibiotics harms the commensal 
microbiota.
- Research funding for development of anti-
microbial drugs is scarce and Big Pharma 
does not see high enough potential for future 
profits or return of investment.
- Urgent need for new antimicrobial 
therapies and alternative strategies 
to treat bacterial diseases
- Developing new treatments against 
drug-resistant bacteria
- Circumventing resistance mecha-
nisms, by using new natural com-
pounds with antibacterial activity, 
focusing on compounds that do not 
increase the selection pressure
- Prevention of inappropriate use of 
existing antibiotics
- Species-selective antibacterial treat-
ments for protection of commensal 
microbiota
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fill in this gap, but the methods involved need to be applied 
with good background knowledge on the molecule in ques-
tion, related molecules, and ligand complexes and any other 
available biological data on function, binding, and mutants. 
For this purpose, details from the literature, reflecting experi-
ments made by researchers, who are focusing specifically on 
the particular molecules, as well as sequence data and infor-
mation about solved related structures, are of outmost impor-
tance. A common strategy is to begin crystallization trials 
with the goal of obtaining experimental structures over the 
long term to give more accurate data, while simultaneously 
employing the bioinformatics approach to construct a 3D 
structure model in order to have structural data for immediate 
use. This strategy has proven valuable in several projects; for 
example, the 3D model of vascular adhesion protein-1[3] was 
first utilized to study its peptide-binding properties[4,5] and to 
locate the N-glycosylation sites,[6] before solving the first X-ray 
structure of the protein.[7,8]
2.1.2. Template-Based Modeling
Template-based modeling relies on the available experimental 
structures and includes both traditional comparative modeling 
(also called homology modeling) and automated template-based 
methods.[9–11] Both methods consist of four steps: (1) retrieval 
of target and related sequences and identification of known 
structures to be used as templates; (2) sequence alignments for 
modeling; (3) building the 3D structure for the target protein 
by copying parts of the template structure; and (4) building the 
side chains and unaligned loops including refinement of the 3D 
model (Figure 2). Various computational approaches have been 
developed to assess the quality of the 3D models, which take 
into account the molecular environment, hydrogen bonding, 
secondary structure, solvent exposure, pairwise residue inter-
actions, and molecular packing.[12] The extent of modeling can 
vary from introducing the side chain for a mutant form of the 
known protein structure to modeling a novel conformation not 
Adv. Healthcare Mater. 2017, 6, 1700258
Figure 1. Examples of key technologies enabling drug development.
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seen in the available structures of that protein, modeling the 
complete protein, or modeling a small molecule ligand bound or 
a protein–protein complex with a larger interface of interaction.
A 3D model that is based on a template structure with a very 
high sequence identity can be extremely useful to access site-
specific mutants, for example, in designing specific mutations 
to test a structural or functional hypothesis, interpreting experi-
mental results from functional studies with mutants,[13] and in 
understanding why certain variants of a protein have improved 
catalytic properties[14,15] or may cause a disease.[16,17] Such model 
structures can also be instrumental for planning protein engi-
neering of more complex constructs, for example, single-chain 
avidins based on the tetrameric structure capable of recognizing 
multiple ligands.[18] Furthermore, structural models can predict 
species-specific ligand-binding properties, since the sequence 
identity between orthologous proteins in human and in model 
organisms is typically high, and structural models for ortholo-
gous proteins are thus reliable enough for the comparison of 
binding sites. For example, the sequences of human and mouse 
vascular adhesion protein-1 (hVAP-1 and mVAP-1, respec-
tively) are 83% identical.[19] However, pyridazinones, which 
are potent noncovalently binding, anti-inflammatory inhibitors 
designed toward hVAP-1, do not effectively inhibit the function 
of the mouse protein.[20] The 3D model of mVAP-1 successfully 
explained why the mouse cannot be used as a model organism 
for the design of inhibitors against hVAP-1 (Figure 3A).
Since structural models are predictions, they include varying 
degrees of error and misinformation. An estimation of the relia-
bility of the model can be obtained from the level of sequence iden-
tity with the template structure(s). However, even when a family 
of proteins shares low sequence similarity, the fold is conserved 
and key structural and functional features are often retained 
across the family.[21] Multiple sequence alignments together with 
structure-based sequence alignments of related structures can 
reveal the structurally conserved and variable areas, providing 
valuable information that can then be used to improve the align-
ment between the template and model sequences.[22] Additional 
guiding information can be obtained from various databases and 
from the literature on the likely importance of key residues in 
the family; for example, reports on effects of engineered muta-
tions on binding or catalysis and whether residues positions are 
exposed to a binding cavity.[23] Such knowledge-based approaches 
(Figure 2) have been valuable in many studies and significantly 
increased the reliability of the modeling results.[3,24,25] Often it is 
not even necessary to model the entire protein, and this is fre-
quently useful when the overall sequence similarity is low and 
Adv. Healthcare Mater. 2017, 6, 1700258
Figure 2. Association cloud for knowledge-based protein modeling.[1–6]
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the overall alignment is unreliable. For many purposes, a model 
structure limited to the ligand-binding site is adequate, if the 
binding site residues and their spatial arrangement are reason-
ably well conserved. Such binding site models can be used, for 
example, for designing novel ligands, analyzing species-specific 
ligand-binding properties, discovering targets for polypharmaco-
logical approaches and for predicting off-target proteins for drug 
compounds or drug candidates.[34]
2.1.3. Computational Approaches Utilizing the Structural Data in 
Drug Design and Discovery
There are multiple rational and innovative ways of exploiting 
molecular structures in drug design, discovery, and 
development.[26–31] The most common 
and straightforward approach is to simply 
examine the molecular structures with a 
suitable software to draw insights. Visual 
analysis of target protein–ligand interac-
tions can give ideas on how to improve the 
binding affinity of the ligands, for example, 
by introducing a polar functional group that 
would form a new hydrogen bond or a non-
polar group to anchor the ligand to a hydro-
phobic pocket nearby. Calculation of so-called 
molecular interaction fields to characterize 
the binding site can further increase the 
knowledge of the different functional group’s 
contribution to the binding interaction.[32] In 
cases when we do not know exactly where 
the ligands bind, there are several tools that 
can help identify the possible ligand-binding 
sites in the target protein structure.[33] Simi-
larly, protein–protein interfaces can be com-
putationally evaluated for possible “hot spot” 
binding regions in order to target them with 
putative protein–protein interaction (PPI) 
inhibitors.[34–36] Moreover, in the absence 
of the experimental target–ligand complex 
structure, molecular docking or protein–pro-
tein docking can be used to predict ligand-
binding modes to assist in the interaction 
analysis.[37–40]
Predicting ligand-binding modes by 
docking still has many challenges. The flex-
ible nature of small compounds is usually 
taken into account by the current docking 
algorithms, whereas the estimation of 
ligand-binding affinity[41] and the conforma-
tional flexibility of the large protein struc-
tures including changes in side chains, 
backbone, and domains upon ligand binding 
is more complex to address.[42–45] To reveal 
limitations on the docking software perfor-
mance, it is advisable to test several docking 
programs and analyze the consistency of 
the predicted ligand-binding modes. If pos-
sible, the performance of a certain docking 
program should be tested by control docking, where the ligand 
from the X-ray structure of a protein–ligand complex is docked 
back to the crystal-binding site and the docking result is com-
pared with the original X-ray complex. The control docking 
of berenil (an antitrypanosomal drug; Figure 3B) and pen-
tamidine (used to treat pneumocystis pneumonia; Figure 3C) 
into human diamine oxidase (hDAO) structure gives a good 
example of a successful control docking result. Both of them 
bind in the minor groove of DNA, but also to hDAO, which is 
an off-target for several diamine derivatives used as drugs.[46] 
Docking methods produce an ensemble of molecular poses 
ranked by a scoring function that attempts to evaluate the 
binding energy between the target and the ligand.[47,48] Since the 
highest scoring result may not reflect the actual binding mode 
due to the limitations in scoring functions,[47,48] it is important 
Adv. Healthcare Mater. 2017, 6, 1700258
Figure 3. A) Homology modeling in understanding species-specific binding properties of the 
ligand-binding sites of human and model system proteins. Homology model of mouse VAP-1 
(mVAP-1) provides explanation why pyridazinone (pink sticks), an anti-inflammatory inhibitor 
designed toward human VAP-1 (hVAP-1) does not inhibit mouse protein. Asp180 (cyan) and 
Tyr448* (blue; from the other monomer) of hVAP-1 form hydrogen bonds with the inhibitor. In 
the homology model of mVAP-1, the residues corresponding to Asp180 and Val209 (cyan) in 
hVAP-1 are replaced by larger glutamate and leucine residues (yellow) blocking pyridazinone 
binding to mVAP-1.[7] B,C) Successful control docking using Glide in the Schrödinger suite. 
Control docking results of berenil (B) and pentamidine (C) (yellow) to human diamine oxidase 
(hDAO) are in well agreement with their experimental binding mode (green): pentamidine 
(C) binds into a side cavity that is filled by water molecules (red spheres) in the berenil complex 
(B). Prior to the docking experiment, these water molecules should be removed, whereas the 
inhibitor-binding water molecules near TPQ should be restored in the binding site. D) Knowl-
edge-based analysis of Glide docking results. hDAO is involved in histamine and ethylhista-
mine degradation but there is no X-ray structure available for the hDAO-substrate complex. 
The analysis of methylhistamine docking results reveals two similar binding modes but only the 
best-ranked pose of methylamine (green) has geometrically right position for the hydrogen atom 
(yellow) that is abstracted by the catalytic base (Asp386) during catalysis (Lopes de Carvalho, 
unpublished results).
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to consider all the ligand-binding modes predicted by compu-
tational docking studies, taking into account ligand similari-
ties,[49] protein–ligand interaction fields based on many X-ray 
structures,[50–52] and existing experimental data. Among others, 
binding strength of related molecules, effects of mutants on 
binding strength or catalysis, and effects of different inhibi-
tors and knowledge on the catalytic mechanism should be 
taken into account. For example, copper amine oxidases bind 
substrates covalently to the topaquine (TPQ) cofactor and 
knowledge on the catalytic reaction mechanism is crucial for 
the analysis of docking results (Figure 3D).
Molecular dynamics (MD) simulations have been widely 
used in studying the conformational flexibility of proteins, 
other biomolecules, as well as small molecules.[53–55] An anal-
ysis of the conformational space of a small molecule can aid 
in the molecular design of new therapeutic compounds. MD 
simulations were, for example, utilized in the design of tri-
valent glycoclusters as new immunostimulatory adjuvants[56] 
(Scheme 1). Such immunostimulants of carbohydrate origin 
have gained significant recent interest in medical biotechnology 
and drug development. Furthermore, MD simulations can help 
one explore alternative conformations of drug targets,[57,58] aid 
in locating transient pockets at protein–protein interfaces, or 
even be a guide toward personalized medi-
cine when studying the effect of a single 
nucleotide polymorphism (SNP) on target 
protein–ligand interactions.[59] MD is also 
frequently used for refining protein models 
and docked ligand–target complexes or for 
examining their stability.[24,60,61] However, 
simulations may as well be counterproduc-
tive and add additional uncertainty and error 
to a model. The free binding energy of the 
bound ligands can also be evaluated with the 
help of MD simulations, though it requires 
sufficient conformational sampling.[62] In 
fact, in addition to the inaccurate molecular 
mechanics force fields, insufficient confor-
mational sampling remains an important 
limitation of MD simulations, even though 
various enhanced and biased sampling 
methods have been developed to help over-
come this challenge.[63,64] For example, large 
conformational changes related to the func-
tion of proteins such as inactive–active or 
closed–open transitions can be investigated 
with biased MD methods such as targeted 
molecular dynamics (TMD).[65]
A very often used method in lead dis-
covery is virtual screening (VS).[62,66–68] In 
this approach, large compound databases 
that can contain up to millions of mole-
cules are screened computationally to find 
potential bioactive compounds against a 
particular target.[69,70] For example, novel 
opioid analgesics with reduced side effects 
were recently discovered from over three 
million molecules using a VS approach.[71] 
The procedure starts by preparing the data-
base compounds; for example, 2D structures are converted to 
3D structures; stereoisomers, tautomers, and possibly alterna-
tive conformers are generated. It is also useful to prefilter the 
compounds with unwanted properties from the database, for 
example, according to the Lipinski Rule of Five (Ro5)[72] that 
aims to remove compounds that might not be orally bioavail-
able. The actual screening criteria may be based on either the 
2D or 3D structures of known active compounds or the struc-
ture of the binding site in the target protein, or both. In struc-
ture-based VS, one also needs to carefully select if the target 
protein structure is a single model, an experimental structure, 
or an ensemble of target conformers and prepare it by, for 
example, adding hydrogen atoms, checking the protonation 
state of the binding site residues, and including possible cofac-
tors, metal ions, or conserved water molecules involved in the 
ligand binding. Ligand-based VS utilizes, for example, phar-
macophore modeling or similarity searches to find matching 
compounds from the database, whereas structure-based VS 
includes docking and scoring of all the database compounds 
in the target-binding site.[73,74] To address the uncertainty of 
scoring functions that rank the compound poses, one should 
always perform the control docking and try different soft-
ware if possible. If there are many known active compounds, 
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Scheme 1. Molecular design of immunostimulatory carbohydrate assemblies. Glycoimmu-
nology is emerging as a highly topical research area with significant interest directed toward 
development of a Th1 and Treg response inducing immunostimulants. Synthetic β-(1→2)-
linked mannobiose derived trivalent glycoclusters, mimicking the cell surface oligomannans of 
C. albicans are now shown to possess considerable potential as immunostimulatory adjuvants 
both in vitro and in vivo for specific allergen immunotherapy (SIT), with superior activity profiles 
compared to the earlier described CpG-ODN and monophosphorylated lipid A adjuvants.[30–32] 
Such oligovalent synthetic carbohydrate assemblies, also subjected to structural and confor-
mational analysis by NMR spectroscopy, molecular modeling, and MD simulations,[32] may 
potentially mimic the natural display of high-affinity ligands[33] and rapidly enter the market as 
components in allergy vaccines, as such or in combination with existing allergens, including 
birch, grass, and ragweed, with long history and efficacy and safety data. Chemical structure of 
synthetic β-(1→2)-linked mannobiose derived trivalent glycocluster. The 3D conformation of 
the glycocluster at the background is based on the MD simulation studies of the molecule’s 
minimum energy conformation (shown as sticks; atom color code: gray – carbon; red – oxygen; 
blue – nitrogen; hydrogen atoms are omitted for clarity).
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a retrospective docking analysis can be performed to see how 
well the VS protocol can enrich the known active compounds to 
the group of top-ranked compounds from a database of decoys. 
In addition, consensus scoring that combines several different 
scoring functions could be employed to help selecting the top 
hits for biological testing.[75] To reduce the number of hits 
selected, the best-ranked compounds can be further filtered, for 
example, according to chemical diversity, ease of synthesis, or 
patentability (Figure 4). General pitfalls in VS have been com-
prehensively reviewed in ref. [76]. In practice, VS can identify 
molecules that are true binders, but also assign nonbinders 
among the top-ranked, or miss true binders.
Quantitative structure–activity relationships (QSAR; also 
called quantitative structure–property relationships, QSPR) 
is a ligand-based approach commonly used for lead optimiza-
tion and selection of candidate compounds for synthesis or 
testing.[77,78] The QSAR methods aim at establishing a quan-
titative correlation between the chemical structure of a set of 
molecules and their experimentally known biological activity 
(e.g., binding affinity or G-protein activation[78]) or property 
(e.g., ADMET properties such as solubility, permeability, liver 
enzyme metabolism, or heart toxicity[79,80]). QSAR models are 
used to predict the activity and property of untested compounds 
on the basis of their chemical structure. Traditional 2D-QSAR 
employs only the 2D structures of compounds and is mostly 
used to optimize the substituents on a common chemical scaf-
fold structure. 3D-QSAR methods also take into account the 
3D structure of the compounds and are widely used in drug 
design. When one builds a QSAR model (Figure 5), the gen-
eral underlying assumptions and limitations of QSAR mode-
ling should be taken into account, and the model’s applicability 
domain has to be clearly defined to obtain a useful and accept-
able model with predictive power.[77] See Table 2 for a summary 
of the critical aspects, risks, and limitations that should be 
taken into account when using the computational approaches 
we have discussed above.
2.2. Computational Network Modeling for Polypharmacology
Computational network modeling is a widely used approach 
to describe and understand complex biological systems. It has 
become a key tool to integrate many omics data sets, and to 
investigate questions ranging from onset of disease, as support 
for diagnostics and therapeutics, and to aid drug target iden-
tification.[81–84] There are many types of computational mod-
eling approaches, supported by excellent software tools.[85–89] 
For example, models can be presented as networks, where 
the nodes represent the genes or proteins of interest, and the 
edges between them describe the dynamic interaction between 
them.[90] A recent example of such a network model is a pro-
teome-scale map of the human interactome network.[91]
The network control theory is a powerful tool for analyzing 
network models.[92] In the network, control is sought over a given 
Adv. Healthcare Mater. 2017, 6, 1700258
Figure 4. A general virtual screening workflow.
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set of targets, in the sense of being able to change their configu-
ration through external interventions on some well-chosen input 
nodes in the network, taking advantage of the network topology. 
The intuition behind this problem formulation is to find suit-
able combinations of drug targets acting on some nodes of the 
network, which through their cascading effect throughout the 
network may change the target’s quantitative configuration from 
an unfavorable (e.g., disease-specific) setup to a favorable one 
(e.g., physiological). The dynamics of such a network may be 
described as a discrete linear dynamical system, and the target 
controllability problem is to find the smallest number of input 
nodes that make the system target controllable.[93]
For example, one can identify a set of cancer-specific genes 
that are required for survival of cancer cells using a disease-
specific network model. The target controllability problem in 
this case is to predict minimum combinations of drug targets 
and drugs acting on them, which may be able to switch off the 
disease-specific genes for any patient-specific starting configu-
ration of the network (Figure 6). We are currently developing 
a disease-specific network for cancer applications using a big 
data-driven approach to build a directed protein–protein inter-
action network based on an automatic scanning of several data 
sources, including the KEGG pathway database, Pathway Com-
mons, and WikiPathways, as well as the DrugBank and a list 
of FDA-approved drugs to identify drug targets in the network 
[RogojinTR2016]. The tool may even include user-generated 
data on, for example, patient-specific highly expressed genes. 
Finally, the tool compares the generated network with cancer-
specific essential gene data from the COLT-Cancer database.[94]
However, formulation of the target controllability problem 
as an optimization problem is computationally hard, even if 
simplified to focus just on the structural part of the network, 
while ignoring its precise weights.[95] More specifically, the time 
needed to find the smallest control for a given network grows 
exponentially with the size of the network. Several alternative 
solutions aiming for fast approximations of the optimal solutions 
exist, including approaches to obtain therapeutic suggestions and 
cell type-specific combinations of drugs.[93,95,96] If the network 
model takes patient-specific data into account, these suggestions 
may even contribute to personalized therapeutics. Importantly, 
one may also obtain suggestions for repurposing existing drugs, 
currently in use for other types of diseases, thus positively con-
tributing to the problem of expensive drug discovery.
The network controllability problem does not come without 
limitations. Its most clear drawback is that it is only applicable 
to linear networks; this limits its applicability to a wider, often 
nonlinear, set of biological interactions. Another limitation is 
that it assumes a simplified model of drug effects, ignoring pos-
sible powerful off-target effects and synergistic effects of drug 
combinations. Finally, another limitation is that of the math-
ematical model assuming arbitrary input functions, which may 
correspond to unrealistic or nonviable combinations of drug 
dosages and assumptions of their decay rate in an organism. 
Addressing all these issues should improve the wider applica-
bility of the network controllability approach in the biomedical 
and the pharmaceutical domain.
3. Nanotechnology as an Enabling Tool  
in Drug Development
Nanomedicine, “the application of nanotechnology to health,” 
makes use of nano-sized tools in the form of nanomaterials 
for diagnosis, monitoring, control, prevention, and treatment 
Adv. Healthcare Mater. 2017, 6, 1700258
Figure 5. General workflow for building a QSAR model.
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Figure 6. A directed protein–protein interaction network model for pancreatic cancer, constructed based on UniProtKB and literature data. The network 
nodes targetable by drugs from the DrugBank database (blue). Cancer-essential nodes from the COLT database (red). The rest of the protein nodes 
of the model (yellow).
Table 2. Limitations, risks, and critical issues involved in using common computational approaches in drug discovery, design, and development.
Computational approach Purpose in the drug design/discovery process Limitations, risks, and critical issues Reference
Template-based modeling
Traditional and automated  
comparative modeling
Provides a structural model in the absence of 
an experimental structure; useful models can 
aid a lot in structure-based drug design efforts.
Requires critical thinking and careful integration of all 
possible data; the risk of becoming a “black box” method 
can be avoided if the sequence alignment can be carefully 
built, analyzed, and adjusted.
[17–20]
Drawing insights from the structural data
Examining molecular interactions Understanding the key interactions between the 
binding partners leads to optimization.
Requires critical thinking and careful integration of all 
possible data, since the experimental structures can be 
incomplete or sometimes even wrong; good knowledge 
on the character of the noncovalent bonds in ligand–pro-
tein interactions is essential.
[21]
Molecular dynamics simulations Mechanistic understanding of motions of 
molecules, refining of model structures, pro-
duction of alternative molecule conformations, 
estimating of binding affinity of ligands.
Sufficient sampling is required; a lot of computational 
resources are needed to perform especially the longer 
simulations; currently, atomistic simulations can reach 
only about 1 ms time scale; MD force fields are still inac-
curate in describing systems, where quantum effects are 
important; simulation of a modeled structure may add 
additional error and uncertainty to a model.
[22,23]
Virtual screening
Molecular docking Predicting the ligand-binding site and pose and 
the estimation of the binding energy enables 
the ranking of the docked compounds and 
selection of the candidate hits for biological 
testing.
Accuracy of the current scoring functions is limited; 
validation of the selected scoring function should 
be performed if possible; consensus docking and or 
scoring might be needed to aid in selecting the best hits; 
results dependent on the target structure quality and 
conformation.
[22,24–26]
Pharmacophore-based screening Facilitates the discovery of novel compounds 
that have the same chemical features than the 
known active compounds.
Alignment of different ligands can be challenging; bioac-
tive conformation might not be known.
[27]
Quantitative structure–activity relationships
Traditional (2D)-QSAR and 3D-QSAR Predicting the activity or other properties 
of novel compounds on the basis of their 
chemical structure.
Alignment of different ligands can be challenging; 
biological data must be of good quality; robust number of 
ligands with known activities needed; rigorous validation 
of the models should be performed.
[28,29]
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of disease. The field of nanomedicine consequently covers sev-
eral application areas, including drug delivery, in vitro diagnos-
tics, in vivo imaging, smart/responsive biomaterials, and active 
implants and coatings.[97] In 2005, the European Technology 
Platform for Nanomedicine (ETPN) published a Vision Paper, 
which subdivided nanomedicine into three distinct research 
areas: (1) targeted drug delivery and release (nanopharmaceu-
ticals); (2) nanotechnology-based diagnostics including imaging 
(nanodiagnostics); and (3) regenerative medicine. Since then, 
owing to the interdisciplinary nature of this research field, 
boosted by advances in chemistry, pharmacy, biology, medi-
cine, and imaging, the development of so-called “theranostic” 
nanomedicines that simultaneously possess both diagnostic 
and therapeutic capabilities have further emerged. The preclini-
cally most relevant applications of these involve validation and 
optimization of the properties of drug delivery systems, pre-
screening patients, and enabling personalized medicine.[98]
Nanomaterials essentially bridge the gap between molecules 
and macroscopic materials. Linking to the classical definition of 
nanotechnology, which emphasizes the unique phenomena that 
occur on the nanoscale, nanomedicine takes advantage of two 
such general phenomena: transitions in physico-chemical prop-
erties and transitions in physiological interactions,[99] the latter 
generally referred to as the nano–bio interface. Nanoscale is 
also the scale of function in nature, which is the ideal example 
of a system that functions impeccably on the nanoscale with 
a high degree of optimization regarding involved materials, 
energy consumption, and data handling.[100] Consequently, 
many of the advantages, and risks, of nanomedicine are related 
to these unique physiological interactions that occur on the 
nano–bio interface in the size range between the molecular 
and microscopic scales.[99] Being able to fully control these risks 
have hampered the clinical translation of nanomedicines, and 
regulatory bodies still struggle with the type of characterizations 
that should be carried out in order to introduce safe nanomedi-
cines. The fabrication of nanomedicines is more complex than 
conventional dosage forms,[101] as not only the physicochemical 
characteristics of the nanomedicines dictate their function, but 
also the manner in how each parameter affects functionality 
needs to be known. Emphasis is put on particle size and shape, 
chemical composition, surface charge, and functional groups, 
and both chemical and colloidal stability under relevant condi-
tions, which all are critical material properties that govern the 
nanomedicine behavior in a living system. The last cannot be 
enough emphasized, as the physicochemical characteristics of 
a nanosystem will change after administration, the route of 
administration also being a parameter to take into account. The 
main responsible for this phenomenon is the protein corona 
formation that occurs upon contact with a biological fluid. 
Hence, the nanoparticle has a “synthetic identity” describing its 
characteristics upon standard materials characterization condi-
tions, but acquires a “biological identity” after being introduced 
into a biological/physiological environment.[102] Further, both 
physical and biological barriers such as diffusion, flow and 
shear forces, induced aggregation, phagocytic sequestration, 
and premature clearance[103] need to be overcome to reach the 
target, which can be difficult to predict without methods stand-
ardized for the purpose. Methods for assessing drug molecule 
ADME(T) properties have been developed throughout the 
years, but additional levels of complexity arise for the applica-
tion of these to nanosystems. Here, on one hand computational 
approaches (see Section 2) for predicting nanoparticle in vitro 
and in vivo behavior,[104] as well as relevant model systems (see 
Section 5) combined with advanced imaging techniques will aid 
in elucidating a more realistic scenario for nanoparticle perfor-
mance and function in order to enable faster translation.
3.1. Nanopharmaceuticals
The field of nanopharmaceuticals deals chiefly with the devel-
opment on nano-sized drug delivery systems, where the nano-
material serves as the drug carrier. Such nanoformulations are 
expected to increase the therapeutic outcome in many ways, due 
to their ability to guide drugs to the desired site of action with 
increased precision (targeted drug delivery) and provide con-
trolled release, enhance drug solubility and rate of dissolution, 
extend the drug half-life in the body, improve the therapeutic 
index, reduce the dose needed, increase the drug stability, pro-
mote the transport across biological barriers, decrease drug 
resistance, and reduce toxicity and immunogenicity. These 
capabilities are essentially built into the nanomaterial carrier 
by rigorous materials design. Nanopharmaceuticals have con-
sequently been defined by Rivera et al. as: “”Pharmaceuticals 
engineered on the nanoscale, that is, pharmaceuticals, where 
the nanomaterial plays the pivotal therapeutic role or adds addi-
tional functionality to the previous compound.”[105] Nanofor-
mulations of small-molecular compounds reached the market 
more than 20 years ago, when Doxil, a liposomal anticancer 
formulation, was introduced, and cancer is still accounting for 
approximately about 2/3 of nanotherapeutics in development. 
The “real” benefit of cancer targeting by nanomedicines is cur-
rently being debated in the literature (see Section 3.3.1 below), 
but it is clear that proven benefits such as increased drug sol-
ubility and stability, prolonged circulation time in the body, 
improved biodistribution, reduced toxicity, and enhanced thera-
peutic efficacy via nanoformulation approaches have resulted in 
approval of a number of cancer nanomedicines.[106] However, 
all drug molecules will not benefit from being nano formulated, 
hence the rationale should be carefully contemplated and war-
ranted. For instance, there is currently an exponential growth 
in interest for biological drugs, which could indeed benefit 
from being formulated as nanopharmaceuticals due to their 
sensitivity and unfavorable properties, making them chal-
lenging for many conventional formulations. In vivo gene 
delivery is another area, where nanoformulations have recently 
shown promising advances in protecting the fragile biomol-
ecules during delivery. The typical nanoscaled carriers of today 
are increasingly complex systems, with sophisticated release 
mechanisms that can release the drug upon different endog-
enous (pH, temperature, biochemical reactions) or exogenous 
(light, magnetic field, ultrasound) stimuli.[107] Notably, “mole-
cular machines” are often utilized as gatekeepers; the princi-
ples of which were awarded the Nobel Prize in chemistry in 
2016. While accumulated advances have spurred high hopes 
of nano-sized tools to revolutionize treatment of many diseases 
in a fashion that currently cannot be achieved with conven-
tional dosage forms,[108] it is most likely not the most complex 
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systems that will actually reach the patients, as the more sim-
plified systems are generally easier translated.[109]
3.2. Nanodiagnostics
Nanoscopic imaging probes have already made significant pro-
gress in overcoming limitations associated with conventional, 
molecular imaging agents.[110] The nanostructures essentially 
can be either (1) inherently detectable by optical and biomedical 
imaging techniques, or (2) serve as carriers for existing, molec-
ular imaging agents.[111] Inorganic nanostructures are readily 
utilized as biomedical imaging probes due to their inherent 
detectability by a variety of different imaging modalities, for 
example, quantum dots, QDs, for optical imaging and super-
paramagnetic iron oxides, SPIONs, for magnetic resonance 
imaging (MRI). Due to the heavy metal composition of QDs, 
hampering their in vivo imaging translatability,[112] research 
efforts have been put into developing alternative probes for 
optical imaging. These include carbon-based nanostructures, 
for example, carbon dots and fluorescent nanodiamonds, as 
well as upconverting nanophosphors (UCNPs). SPIONs in the 
form of ferrofluids are already in clinical use, but due to their 
negative contrast in MRI, other metal oxides such as manga-
nese and gadolinium oxide nanoparticles with positive contrast 
are being developed. Novel nanoscopic MRI contrast agents are 
especially advantageous as constructs in multimodal or thera-
nostic nanoparticulate systems.[113]
When nanoparticles are utilized as carriers for molecular 
imaging agents, traits including cellular uptake and intracel-
lular release ability, capacity to carry high amounts of dif-
ferent compounds, allowing a protective and thus stabilizing 
environment for incorporated agents, and ability to retain the 
cargo within the particle for prolonged times are exploited simi-
larly as in the design of nanopharmaceuticals. Utilizing this 
approach, sensitive fluorophores can be photostabilized and 
the dose of toxic imaging agents such as Gd-based, clinically 
used MRI contrast agents, which are organic complexes of Gd 
ions can be lowered while the imaging time-frame can be pro-
longed owing to retention of the nanocarrier at target sites. For 
both design approaches, the ability of the nanoscopic particles 
to provide access to sites unreachable by the molecule itself 
by crossing of biological barriers and prolonged circulation 
times in the body by changing stealth properties is exploited. 
Moreover, one nanoparticle can carry multiple specific tar-
geting and imaging moieties, thus enabling a multivalent mode 
of attachment increasing avidity, which can enhance both the 
sensitivity of the signal (multiple imaging agents per binding 
event) and the probability for attachment to its target (multiple 
targeting moieties per particle). The imaging modality can be 
chosen depending on the nanoparticle design, where the com-
bination of different nanomaterial constructs can even generate 
multimodal probes.[114] One of the furthermost advantages with 
multimodal probes is that they can provide complementary 
information in one shot, for example, high resolution and high 
sensitivity, associated with the imaging modalities the probes 
are compatible with.[115] While these types of systems are cur-
rently mostly avidly exploited in research, nano-based imaging 
agents have been stated to be important for personalized 
treatment, for preselection of patients that are supposed to ben-
efit most from an intended therapy, and as constructs in thera-
nostic nanomedicines in the future.[100]
3.3. Nanomedical Applications
The ETPN has identified the following diseases as potential 
beneficiaries of nanomedicine: cancer, atherosclerosis, diabetes, 
ocular diseases, Alzheimer’s disease, arthritis, and infectious 
diseases. Overviews of the application areas within these dis-
eases tied to the topics of the review are illustrated in Figure 7, 
and a couple of examples will be briefly introduced. For a com-
prehensive review on the topic, please see ref. [116].
3.3.1. Nanomedicine in Cancer
One of the main difficulties of cancer treatment is to achieve 
sufficient drug concentration at the site of the carcinoma, due 
to the numerous bio-barriers in different organs and cancer tis-
sues. Further, high systemic exposure of anticancer agents leads 
to dose-related toxicity, giving rise to serious adverse effects, and 
resistance to therapeutic agents. The progress of nanotechnology 
during the last decades has imparted high hopes on improving 
especially cancer therapeutics. A multitude of different types of 
nanoparticles, including liposomes, polymersomes, polymeric 
particles, inorganic particles, etc., have been developed for anti-
cancer drug delivery. Nanoparticles can also be designed to elicit 
immune response as nanovaccines for cancer treatment.[117,118] 
Nanoparticles typically accumulate passively in tumor tissue 
due to the enhanced permeability and retention (EPR) effect,[119] 
but the Holy Grail in nanomedicine is to be able to achieve 
even more selective delivery via active targeting. Porous nano-
materials are one type of nanoparticles that are widely used 
for drug delivery applications, due to their unique properties, 
including nano-sized pores for loading of both small molecules 
and large biomolecules (proteins, nucleic acids), good biocom-
patibility, biodegradability, and flexibility in terms of applicable 
surface functionalization strategies (Figure 8). Mesoporous 
silica (MSNs) and porous silicon (PSi) are typical examples, that 
have, for example, been functionalized with the small-molecular 
ligands folic acid and glucose,[120,121] as well as tumor homing 
peptides such as CooP and iRGD, resulting in higher accu-
mulation at the tumor site via active targeting.[122,123] However, 
the clinical benefit of active targeting has been questioned,[103] 
and most anticancer nanomedicines on the market still rely on 
passive tumor targeting. Protein corona formation in vivo may 
hamper the access of the targeting ligands to cell surface recep-
tors, and PEGylation was for long applied as a universal strategy 
to hide nanoparticles from the immune system (a.k.a. stealth 
particles). Certainly, the real-life scenario is more complex, but 
detailed investigation of the protein corona formation has not 
surfaced before quite recently. Critique has also been directed 
toward the in vivo models used to evaluate cancer nanomedi-
cines, favoring tumor accumulation due to the EPR effect in 
mice, but with poor translatability to human cancers.[124] Such 
misconceptions have led to overexaggerated expectations when 
it comes to the success of cancer nanomedicines. However, 
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recent exhortations call for “looking beyond the targeting” and 
focusing on the other aspects and clinical advancements of 
nanomedicine. For example, the first generic cancer nanomedi-
cine was recently approved, and the delivery of two chemother-
apeutic drugs in a therapeutically synergistic ratio by a single 
formulation and triggered release strategies are currently being 
evaluated in phase III clinical trials.[124]
3.3.2. Nanoantibiotics: Nanomedicines as Modern-Era Antibiotics
The challenging and dynamic situation in infectious diseases 
requires the investigation of novel platforms to bring alternative 
treatments for bacterial diseases. New antimicrobial drug devel-
opments cannot catch up with the microbial pathogens’ fast and 
frequent development of resistance in a timely manner. Conse-
quently, there have been efforts to create alternative treatments 
by employing antibacterial nanomaterials, to which pathogens 
may not be able to develop resistance.[125] Antibacterial nano-
particles have been reported to offer advantages in reducing 
acute toxicity, overcoming resistance and reducing the cost, 
when compared with conventional antibiotics.[126,127] Most of 
the studies to date have focused on inorganic nanoparticles con-
taining silver,[128] gold,[129] cupper,[130] zinc, titanium oxide,[131] 
and cerium oxide as antibacterial agents.[125] These materials can 
inherently exert antibacterial activity, and can further, similarly 
Adv. Healthcare Mater. 2017, 6, 1700258
Figure 7. Examples of nanotechnology applications, including diabetes, wound healing, and combating bacterial resistance. A) Development of patient-
friendly insulin delivery nanoparticle formulations. Various properties of nanoparticles can be tailored to exploit transepithelial transport mechanisms 
to facilitate systemic insulin delivery. Nanoparticles prepared with bound ligands for specialized receptors expressed on epithelial cell surfaces can be 
transcytosed across epithelial barriers. Ultrasmall nanoparticles with hydrophilic coatings can exploit paracellular diffusion to bypass epithelial barriers. 
Nanoparticles with tuned lipophilic physicochemical properties can permeate across epithelial barriers through a transcellular pathway. Cationic charged 
nanoparticles can exploit the adsorption-mediated transcytosis pathway for transport across epithelial barriers. Finally, nanoparticles that are transported 
across epithelial barriers by antigen sampling microfold cells (M cells) could be developed. Reproduced with permission.[8] B) The desferrioxamine-loaded 
hydrogel nanofibrous scaffolds can interfere with the required prolyl-hydroxylases cofactors by acting as Fe2+ chelators and upregulate the expression of 
Hif-1α, leading to a significant increase of the neovascularization. Reproduced with permission.[9] Copyright 1994, Taylor and Francis. C) Illustration of 
the enhanced bacterial killing mechanism of prickly Zn-CuO nanoparticles by a multidimensional nanopiercing process inducing accelerated cytoplasma 
leakage on the bacterial cell wall. Reproduced with permission.[10] Copyright 2011, Bentham Science Publishers Ltd.
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as for imaging agents, be used as constructs in systems addi-
tionally used for efficient delivery of novel antibacterial com-
pounds. These strategies enable bacterial attack on many fronts, 
making it significantly more difficult for microbes to develop 
resistance simultaneously toward all modes of action.[132] 
Further, the ability of zinc-doped CuO prickly nanoparticles 
to combat antibacterial resistance via physical methods,[133] 
was recently portrayed in the media as a promising means of 
“winning the war against superbugs.”[134] Importantly, these 
physically acting nanomaterials can further be combined with 
chemical strategies, that is, loading of drugs to the same nano-
system or used in combinatorial therapy, thereby synergistically 
increasing their effect.[135] The field of nanoantibiotics awak-
ened later than the field of cancer nanomedicine. Consequently, 
the concepts and lessons learned during the development of the 
cancer nanomedicine field may enable avoiding previous pit-
falls and boosting clinical advancement.
3.3.3. Nanomedicine in Wound Healing
Nanomedicine can elicit different functions in the wound 
healing process at the different stages of inflammation, pro-
liferation, and remodeling,[136] and the desired action of the 
nanomaterial can be structural or therapeutic. Different elec-
trospun nanofibrous scaffolds have been developed for wound 
healing, the structure of which simulate the topographic 
appearance of endogenous extracellular matrix (ECM). For 
instance, electrospun photo-crosslinkable gelatin-hydrogel 
formed fibrous scaffolds can support vascularization and skin 
flap regeneration. Desferrioxamine-grafted fibrous scaffolds 
can induce Hif-1α expression and activate angiogenesis in dia-
betic mouse models.[137] Besides the nanofibrous scaffolds, gold 
and silver nanoparticles have also exhibited inherent wound 
healing properties, for reasons that are still unknown.[138,139] 
In addition, nanoparticles and nanofibers have been utilized 
in combination. For example, antibacterial silver-containing 
nanofibers have been fabricated for wound healing purposes. 
The greatest benefits have been achieved by combining nano-
materials as constructs in macroscopic material structures via 
suitable manufacturing technologies, for example, electrospin-
ning and 2D/3D printing (see Section 3.4).
3.4. Tailored Approaches for Nanomedicines within Drug 
Development and Diagnostics
The number of nanomaterials in the pharmaceutical and 
medical field has almost exponentially increased over the past 
15 years, and predictions of the nanotechnology markets esti-
mate a growth to tens of billions of dollars in the near future. 
Within the drug development process, the unique properties 
associated with nanomaterials can be exploited in a multifaceted 
manner. In the drug discovery phase, compounds with prop-
erties unfavorable for proper therapeutic efficacy could be for-
mulated as nanopharmaceuticals. For early drug development, 
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Figure 8. Porous materials in development for cancer treatment. A) Hollow-structured porous silica, B) diatom, C) porous silicon nanoparticle, D) gold 
nanocage, E) porous magnetic particle, and F) polymer-based porous nanoparticle. Reproduced with permission.[11] Copyright 2010, Springer. Repro-
duced with permission.[12] Copyright 2009, Elsevier. Reproduced with permission.[13] Copyright 2011, ACS. Reproduced with permission.[14]]
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therapeutic and diagnostic nanomaterials can be integrated for 
simultaneous monitoring of drug delivery, uptake, safety, and 
therapeutic efficacy. For instance, nanoformulation could be 
part of the screening process, since the nanocarriers platform 
can be generic and not associated with a specific compound. 
The traits associated with nanoscopic carriers have been widely 
studied especially for nanopharmaceutical drug delivery appli-
cations, but regulatory and safety issues are still hampering 
a smooth transition forward for many next-generation nano-
medical products, for which reason a European Nanomedicine 
Translation Hub have been established.[140]
From a commercial point of view, nanomedicine can provide 
benefits by (i) reformulation of existing drug molecules as nan-
opharmaceuticals, either due to previous failure in clinical trials 
due to severe side effects or (ii) by extending the product life 
cycle by extending its patent life as a new product. For instance, 
the active molecules of blockbuster drugs, whose patents 
are set to expire can be reformulated for repatenting them as 
novel products.[141] It has thus been foreseen that in five years 
every Big Pharma company will have a nanomedicine program 
within their pipeline.[142] On the one hand, due to the high 
costs and extensive time periods that are required to develop 
new chemical entities (NCEs), making use of existing drug 
molecules may speed up the process and lower the costs. While 
developing a new drug delivery system is significantly less 
expensive and time consuming than developing a new drug, 
pharmaceutical companies can take advantage of novel drug 
delivery technology as a life-cycle management tool for their hit 
products.[143] This aspect of repackaging an existing drug was 
acknowledged by Gregoriadis already in the 1970s and is com-
monly known as “putting old drugs in new clothing.”[144] On the 
other hand, active agents that failed in clinical trials in the form 
of conventional formulations due to unacceptable toxicity or 
pharmacokinetic profiles, poor bioavailability, solubility issues, 
or physical/chemical incapabilities, may overcome these issues 
by being reformulated as nanopharmaceuticals.[145] While these 
approaches are already reality, the future visions that have been 
put forward can also be more grandiose, for instance, recently 
expressed in a Feature paper in Nature Nanotechnology, “the 
final goal of nanotechnology in medicine is to realize ‘in-body 
hospitals’, that is, smart virus-sized nanomedicines can migrate 
into the microenvironments in the body to provide diagnostic 
and therapeutic functionalities 24 hours a day.[100]”
4. Technologies and Materials for Tailor-Made 
Drug Delivery/Diagnostic Systems
Although a great number of genes contributing to human ill-
ness have been defined over the recent years, genetic variability 
in patients affects the responses to different treatments.[146,147] 
Hence, the molecular base of diseases needs to be specifi-
cally recognized and targeted. For this purpose, scientists and 
clinicians are developing and using diagnostic tests based on 
genetics and knowledge in the molecular mechanisms regu-
lating disease, to better predict the responses of patients and 
to enable targeted therapies for the future.[148] As the indi-
vidual requirements of patients increase, the fabrication of 
drug delivery systems have to adapt and move toward more 
tailored solutions. This includes diagnostic aspects to not only 
identify the most effective treatment for a patient, for example, 
by making use of theranostic nanomedicines, but also the 
production of tailored delivery systems. This chapter aims to 
display what kind of possibilities new technology and novel 
materials can give to support drug development and diagnostic 
approaches.
4.1. Drug Delivery Technology
While early phase research in drug development have aimed 
at identifying potential NCE and to understand their behavior 
in vitro and in vivo, the challenges in this area are to develop 
and optimize carrier systems for any given drug. The adminis-
tration route, the dose needed, as well as the physicochemical 
properties of a drug are playing an important role in this chal-
lenge. The excipients, serving as carriers and formulated along-
side the active ingredient of a medication, have to be chosen 
carefully, and new functionalities need to be introduced, for 
example, by synthesizing new substances enabling specific 
targeted drug delivery. At the same time, all materials used 
have to be approved for pharmaceutical use. According to the 
regulatory guidelines, a manufacturer of a novel excipient has 
to develop safety information appropriate for the intended use. 
The suitability of a material to be used as an excipient in a par-
ticular type of dosage form is based on this information.[149,150] 
Furthermore, the final delivery system, that is, the dosage form, 
has to be manufactured with a suitable technology that both 
ensure that all ingredients maintain their functionality and 
that the therapeutical value is covered. New functional mate-
rials and new manufacturing techniques pave the way for more 
individual patient treatment with tailor-made drug delivery sys-
tems. As most current manufacturing technologies are batch 
processes developed to produce high quantities of a given med-
icine, there is room for development in the area of individual-
ized manufacturing.
4.2. Polymeric Systems for Drug Delivery via Different 
Administration Routes
As there are a multitude of administration routes for medi-
cines, from oral to intravenous, different delivery systems are 
needed for different types of drug release requirements. For 
example, an orally taken drug may be delivered via an inert 
biostable polymer matrix in the form of a tablet. However, 
finding the correct matrix for a specific drug for optimal perme-
ability and diffusion is difficult.[151] To name a few examples, 
lipid-based drug delivery systems are one of the emerging tech-
nologies designed to address such challenges. Moreover, encap-
sulating or solubilizing the drug in lipid excipients can lead to 
increased solubilization and absorption, resulting in enhanced 
bioavailability.[152]
Implantable drug delivery systems have been studied 
broadly and several commercial products are on the market. 
Among the first one was the contraceptive Norplant device, a 
silicone rubber based, nondegradable matrix allowing a steady-
state release of levonorgestrel during a period of five years. 
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However, such diffusion out of the matrix is difficult to achieve 
with larger molecules due to poorer permeability. During the 
1990s, interest was focused on development of bioresorbable 
polymers. By choosing the right polymer, sustained release by 
diffusion, bulk, or surface erosion was obtained. Langer found 
that connective porosity is developed in poly(lactic-co-glycolic 
acid) (PLGA) during bulk degradation, enabling the release of 
larger macromolecules.[153] Simultaneously, the development of 
surface-eroding polymers, especially polyorthoester and poly-
anhydrides, may lead to better-controlled drug release.
Currently, injectable polymeric systems are developed to 
enhance more accurate drug targeting and to avoid a too high 
plasma concentrations of a drug. These injection techniques 
also provide less invasive administration procedures. For inject-
ability, correct rheological behavior needs to be considered, 
requiring development of material suitable for injection. Solu-
tions including in situ formed hydrogel types of polymers[154] 
and drug-containing microspheres[155] are frequently used 
approaches that even may be combined.[156] The in situ formed 
hydrogels are especially interesting for encapsulation of biologi-
cally active components such as viruses and proteins.
4.3. Conventional and New Fabrication Technologies
Most of the needs for production of therapeutical tools are still 
covered by traditional pharmaceutical manufacturing processes. 
Conventional dosage forms such as tablets, capsules, and oint-
ments, and oral and parenteral solutions are manufactured 
with a multitude of established processing techniques typically 
producing high numbers of units in a relatively short time. 
New concepts have been introduced to produce high numbers 
of units in short time. Recently, modernizing efforts have been 
made both in the development of continuous manufacturing 
technologies for large-scale products and of process analytical 
tools (PAT) for real-time quality control of drug products.[157] 
New dosage forms and new or optimized manufacturing pro-
cesses are entering the area of pharmaceutical development 
and manufacturing, providing new possibilities for tailor-made 
solutions for personalized and niche drug products.
For example, computer-aided design (CAD) and printing 
technologies or additive manufacturing technologies have 
recently attracted interest in fabrication of different types of 
dosage forms. The activity in this research field is increasing 
and manufacturing of pharmaceutical products by printing has 
only recently emerged as a new viable option in drug manufac-
turing.[158,159] As an example, in August 2015 FDA approved the 
market authorization of Spritam—a 3D-printed antiepileptic 
product. Printing technologies have been used to further ease 
administration of orodispersible dosage forms. This includes 
using drug-containing ink solutions that can be deposited in 
variable layers and patterns onto these edible substrates, ena-
bling new and more individualized therapy options.[160] Inkjet 
printing as a technology allows very precise deposition of small 
ink amounts, providing a promising technique for individual 
dosing approaches.[161] The combination of different printing 
techniques, such as inkjet printing (noncontact) and flexog-
raphy (contact), can provide solutions to apply different func-
tional layers, offering possibilities for customized drug release 
properties.[162] Whereas printing of liquid inks is a 2D printing 
technique, 3D printing, or free form manufacturing offers the 
opportunity to not only print drug-containing formulations, but 
also medical devices or combinatory products based on digital 
design.[163] Personalizing dosage forms using printing technol-
ogies is a promising outlook for tailored therapies in the clinics 
in the future.[164,165] Combining techniques such as electrospin-
ning and printing can also offer new solutions for creating 
nanostructured materials with advanced functionality and accu-
rate dosing of active substances.[160]
Also, microfluidic techniques are very promising for fabri-
cation and encapsulation of different types of nano/micropar-
ticles.[166] Droplet-based single emulsion and double emulsion 
techniques have been used to produce microparticles for cancer 
drug delivery.[167] For example, doxorubicin-encapsulated PLGA 
nanoparticles produced with microfluidics have been success-
fully tested in mouse cancer models.[168,169] As a technology 
for encapsulation, microfluidics are excellent to combine with 
porous materials. While a major limiting factor of porous mate-
rials in drug delivery applications is uncontrolled premature 
drug release due to the free accessible pores, the pores can be 
sealed with selected functional and responsive polymers to pre-
cisely control the drug release with the support of microfluidics. 
In addition, microfluidics may solve some major challenges in 
fabrication of polymeric particles.[170] For example, the diver-
sity of drugs that can be encapsulated by a certain polymeric 
particle is limited due to the specific physico-chemical proper-
ties of polymers and the exposure to solvent during microflu-
idic process. Encapsulation of porous materials improves the 
drug loading capacity and also provides a possibility for com-
bining drugs in the same delivery system.[171,172] In addition, 
it is possible to introduce different surface functions for both 
inner porous materials and the outer polymer layers, to achieve 
a multifunctional sequential delivery system (Figure 9).[171,172] 
As an example, a multifunctional nano-in-micro platform has 
been fabricated by encapsulating porous silica (PSi) nanopar-
ticles inside pH-responsive polymers for targeted cancer drug 
delivery to colon cancer cells in culture.[173] In addition, it is 
also possible to simultaneously coencapsulate gold nanorods, 
DNA nanostructures, magnetic nanoparticles, PSi, and several 
drugs to a giant liposome using microfluidic double emulsion 
technique.[174] A microfluidic-templated PSi@acetalated dex-
tran nanocomposite has also been shown to precisely deliver 
cancer drug combinations in cell culture studies.[175]
4.4. Materials for Drug Delivery
4.4.1. Excipients for Pharmaceutical Use
There is a wide range of materials available that can be used for 
the fabrication of drug delivery systems. When it comes to oral 
dosage forms such as tablets, capsules, chewable systems suspen-
sions, or solutions, or more recently introduced dosage forms, 
oromucosal films,[176] the choice of excipients always depends on 
the desired administration and functionality.[177] As an example 
for solid dosage in tablet form, functional polymer coatings 
can be applied either on the complete dosage form to achieve 
a protection film or for sustained drug release properties. 
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Furthermore, it is possible to encapsulate or preprocess the active 
pharmaceutical ingredient with suitable excipients to achieve the 
desired effects. Examples are hot-melt extrusion of a drug with 
a polymer and subsequent incorporation of the resulting extru-
dates in a tablet formulation.[178] Liquid dosage forms, either for 
oral or parenteral application, require the consideration of dif-
ferent excipients, such as viscosity modifiers (which could also 
be polymers), pH modifiers, stabilizing agents, and possible pre-
servatives. Topical applications, such as patches or wound dress-
ings with active ingredients, represent an interdisciplinary group 
for different types of drug delivery systems, since liquid and solid 
components can be included, together with dressing material or 
medical devices for the application.
One has to keep in mind that when it comes to excipients, 
the rule “one size fits all” does not necessarily apply. Different 
administration routes but even more important different 
patient groups may require different types of excipients that 
are suitable for the designated age or disease. As an example 
for pediatric patients, acceptable daily intake (ADI) levels and 
recommendations can be found in different databases, for 
example, provided by the European Pediatric Formulation Ini-
tiative (EuPFI, 2016) or the European Food Safety Agency.[179] 
Moreover, as already mentioned above new materials need to 
go through safety and toxicity assessments as described in the 
relevant regulatory guidelines.
4.4.2. Natural Polymers as Drug Carrier Materials
To date a number of polymers have been utilized in biomed-
ical applications. Due to their similarities with the ECM and 
their good compatibility and minimal cytotoxicity, biopoly-
mers of natural origin are particularly attractive options. The 
widely considered biopolymers include collagen, gelatin, 
alginate, chitosan, and cellulose. Some of 
them are existing components of ECM.[180] 
The biopoly mers have been shown to regu-
late division, adhesion, differentiation, and 
migration of cells. There are several reports 
that suggest the beneficial cellular responses 
of biopolymers and their performance over 
synthetic polymers for tissue regenera-
tion.[181–183] Moreover, compared to synthetic 
polymers, biopolymers such as polysaccha-
rides, which are discussed in this review, 
have more available functional groups, for 
example, amino and hydroxyl groups, and 
thus offer diverse and highly selective cou-
pling functionality that can meet the require-
ments in desired applications.
Natural polymers such as polysaccharides 
from different sources, for example, bacterial 
cellulose and cellulose from plants, chitosan, 
and polysaccharides from other origins have 
been studied extensively in applications for 
controlled drug delivery.[184] Cellulose is the 
most abundant natural polymer on earth and 
can be extracted or produced from plants and 
bacteria. With the emergence of nanotech-
nology in designing of biomaterials, nanocellulose, as a new 
form of cellulose polymer has been extensively investigated in 
the use of constructing novel materials. Depending on the pro-
cessing approaches, nanocellulose can be achieved in the forms 
of nanocrystals or nanofibrils, which have elastic moduli in the 
range of 100–200 GPa.[185,186] The strong mechanical properties 
of the materials allow their potential use as load-bearing matrix 
for a broad spectrum of host materials.[187] A few reports have 
shown that the cellulose and nanocellulose have promising bio-
compatibility and hemocompatibility.[188,189] Cellulose as such is 
not biodegradable in the human body due to the lack of cel-
lulolytic enzymes. Degradability of cellulose can be enhanced 
by oxidation.[190] Moreover, the studies of in vitro cell cultures 
of a variety of cell lines and in vivo organ and animal experi-
ments showed that cellulose and nanocellulose have no or only 
low toxicity, the latter comparable to that of salt.[191–194] Studies 
also showed that the wood nanocellulose prepared by TEMPO 
oxidation could support crucial cellular processes during cell 
growth and proliferation of fibroblast cells.[194] Lou et al. suc-
cessfully cultured human pluripotent stem cells in 3D nano-
cellulose hydrogels,[195] which was further commercialized by 
UPM Biochemicals in Finland for 3D cell culture applications. 
The highly porous structure of nanocellulose scaffolds allows 
them to be used as efficient drug carrier systems. To tailor the 
drug-eluting rate for different utilization conditions, loading of 
drug compounds can be realized by simply mixing, covalent 
coupling, or functionalizing the matrix surface, for example, 
creating hydrophobic character that can improve the binding 
ability of drugs.[188,192,196,197] Yet, the impact on the drug activity 
and stability of the chemistry of the matrix surface before and 
after modifications need to be carefully evaluated.
Chitosan is the second most abundant polysaccharide after 
cellulose. Chitosan can be prepared from deacetylation of 
chitin, which is found in the shells of crustaceans, as a waste 
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Figure 9. Schematic depicting the process to synthesize CPP-functionalized multi-drug-loaded 
acid-degradable PSi/polymer nanocomposites (PSi@AcDX-CPP). Microfluidic coflow focusing 
nanoprecipitation is used to prepare multi-drug-loaded PSi/polymer nanocomposites, after 
which CPP is attached to the surface of the nanocomposite through oxime clicking. Reproduced 
with permission.[15] Copyright 2013, ACS.
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product of seafood industries.[198,199] Different than cellu-
lose, chitosan can be hydrolyzed by lysozyme, thus being bio-
degradable.[200,201] Moreover, chitosan is biocompatible and 
also possesses hemostatic, antibacterial, and mucoadhesive 
properties,[188,202,203] thus potentially offering a broad spec-
trum of applications in tissue engineering and drug delivery. 
Compared to hydrogels and scaffolds, nanoparticles based on 
chitosan have attracted more interest.[204–206] In addition, other 
polysaccharides possessing biological properties in their native 
forms or after functionalization, for example, hyaluronic acid, 
chondroitin sulfate, alginates, heparin, as well as plant-derived 
heteropolysaccharides (also called hemicelluloses) have also 
been investigated for various biomedical applications.[188,207]
4.4.3. Biopolymer-Based Stimuli-Responsive Materials
To increase the efficiency of drug delivery, incorporation of 
stimuli responsiveness is one of the most promising strate-
gies to create functional surface properties on the biopolymeric 
matrix or nanoparticles, thus allowing tailored dosing and tar-
geted drug delivery.[208–211] It can be realized by various means 
such as chemical and biochemical functionalization approaches 
to make the natural polymers “smart.” Drug delivery systems 
should apply to externally temperature changes, light and 
electric fields, magnetic fields, or respond to the changes of 
pH, redox potential, and concentration of specific analytes in 
the exposed environment.[212–216] Yet, the adoption of strategy 
should take into account the complex condition of applications 
and the stability of delivered subjects, such as drugs, growth 
factors, and cells.
4.5. Construction of Composites from Natural  
and Functional Polymers
The field of controlled drug delivery drives much current inno-
vation in polymeric biomaterials. The first attempts to achieve 
sustained delivery of macromolecules often failed due to the 
improper biocompatibility of the polymers used, for example, 
polyvinylpyrrolidone and polyacrylamide. Since those early 
days in the 1970s, a vast number of polymer candidates, both 
bioinert and bioresorbable, have emerged as potential matrices 
in sustained and targeted drug delivery applications.[217] Obvi-
ously, the drug administration route places specific require-
ments on the polymer and depends on whether the drug will 
be taken orally, injected, or implanted. Furthermore, the drug, 
a low molecular weight compound or an array of new protein 
and nucleic acid-based drugs, which cannot be administered 
by classical routes will also influence on the matrix choice. 
Thus, both in situ forming injectable hydrogels[218] and inject-
able microsphere systems[219] have been intensively studied 
to enable the delivery of sensitive biological pharmaceuti-
cals.[156] The mentioned new fabrication technologies such as 
3D printing give the opportunity to process new functional 
polymers and composites into defined shapes and scaffolds, 
which can subsequently be used as drug delivery devices. For 
example, the printing of a drug-releasing system may be cus-
tomized in dimensions and shapes. Polylactic acid (PLA) has 
been successfully used to manufacture thin small-sized sheets 
loaded with a drug substance either prior to or after the 3D 
printing process. Furthermore, the impact of the printing pro-
cess on the crystallization of poorly soluble drugs has been 
investigated.[220] Neat porous racemic PLA and PLA-silicon 
dioxide (SiO2, silica) composites have been used to study the 
release of toremifene, a first generation nonsteroidal selective 
estrogen receptor modulator (SERM).[221]
Polylactides have been used as matrix materials for drug 
release, but the clear and sudden changes in structure, for 
example, steep decrease in molecular weight caused by 
enhanced autocatalytic degradation,[222,223] is a problem with 
respect to the controlled release of drugs. Biodegradable, sol-
gel derived SiO2 is known to be biocompatible, and it has been 
used for controlled drug delivery as such. The induced porosity 
in the polymer and the polymer composites containing SiO2-
torimifene particles were able to afford a better control over 
the drug release kinetics, and the release of toremifene citrate 
was adjusted from 30 d to 6 months by adding silica and/or 
pores to the biodegradable polymeric carrier system. Similar 
macroporous polymer/silica composites have been success-
fully applied in regenerative medicine. We have shown that 
it is possible to release silica, calcium, and phosphate ions to 
induce bioactivity and control the formation of bone-like cal-
cium phosphate in vitro[224–226] and in vivo.
Owing to their structural integrity, cellulose in the form of 
fibrils acts as promising matrices for loading drugs.[192,196,197] 
However, chitosan and other water-soluble polysaccharides are 
preferably tailored to form nanoparticles that are more efficient 
in targeted delivery.[202,205] Moreover, construction of compos-
ites from those natural polymers as well as other functional 
polymers or porous nanoparticles can extend the application 
of natural polymers to a broad spectrum of products.[227] This 
will allow combining the benefits of natural polymers and other 
hybrid components. In an example approach, mesoporous bio-
active glass was embedded into a nanocellulose matrix, which 
could deliver Cu2+ as therapeutic ion to promote angiogen-
esis in 3D spheroid culture systems of human umbilical vein 
endothelial cells.[228] Similar mesoporous nanoparticles have 
been applied as nanocarriers to load drugs.[229] This type of 
highly porous materials is suitable for carrying a broad chem-
ical spectrum of drug substances, especially poorly soluble 
drug molecules and can be designed with in-built controlled 
release functionality[230] (Figure 7). Chitosans have particularly 
been applied as hybrid nanoparticles to achieve controlled and 
sustainable drug release profiles.[231] In addition, composites 
of natural polymers and stimuli-responsive synesthetic poly-
mers, for example, thermal-responsive poly(N-isopropyl acryla-
mide), have also been intensively studied as a drug delivery 
device.[188,205,211]
4.6. Modern Approaches for Molecular Sensing and Diagnostics
Diagnostics and sensing are essentially related to the basic phe-
nomena of adsorption and immobilization of biomolecules.[232] 
In a thermodynamic sense, adsorption can be viewed as a pro-
cess that aims to lower the interracial free energy or the sur-
face tension. Biophysically, proteins adsorb because they are 
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large molecules, are amphiphilic in nature, have a relatively low 
solubility, and have an ability to change conformation easily. 
The sensitivity and specificity of sensing are closely related to 
the type of binding as well as orientation and distribution of the 
sensing molecules, not to forget nonspecific binding, whether 
it is caused by intrinsic or external factors.[232] Therefore, tai-
loring of the sensor surfaces onto which adsorption will take 
place becomes very important. Uncontrolled adsorption at a 
surface can adversely affect the activity and stability of the bio-
molecule. On the other hand, immobilized biomolecules may 
be further used for controlling cellular adhesion or increasing 
biocompatibility of, for example, implants.[233] From manufac-
turing point of view, the fabrication of the sensors should be 
easy yet precise and up-scalable.
Printed sensors and diagnostic platforms represent a novel 
approach, where the print substrate is optimized for the ink 
bringing the function to the surface. Printing can be realized 
on a conventional print substrate like paper, but also on, for 
example, glass, metal, or polymers of different types. Tailored 
paper substrates with optimized roughness, surface energy, 
and porosity have been developed on which optical, electrical, 
and electrochemical sensors have been successfully demon-
strated.[234] Key properties of a print substrate controlling the 
ink-setting (spreading and adsorption/absorption) are rough-
ness, surface energy, charge, critical surface tension, and 
porosity.[235,236] Equally important is to pay attention to the ink 
formulation, its composition, surface tension, rheology, and 
colloidal stability.[237] Depending on the material combina-
tions and solubilities, the ink may represent a suspension or 
an emulsion. Emulsions, especially micelles and microemul-
sions, provide a very important possibility for printing poorly 
soluble biomolecules.[238] Optical sensors typically yield a visual 
readout, as a color change, as a result of the ligand-analyte 
reaction.[239] This type of sensor provides qualitative informa-
tion, but is typically very fast, easy to use, and can, therefore, 
be regarded as a potential choice for point-of-care (POC) appli-
cations, even for analysis by a semiskilled nonprofessional, for 
example, the patent himself. These kind of user-friendly, flex-
ible, disposable, robust, affordable, and easily deliverable sen-
sors are believed to find uses especially in resource-limited 
locations such as in developing countries or on the field.[240,241] 
Optical test assays have also been developed for viral diseases 
such as dengue fever[242] and malaria[243] and for measuring 
markers of liver function.[244]
The development of microfluidic paper-based analytical 
devices (µPADs) with improved capabilities for liquid han-
dling have enabled the development of increasingly complex 
devices.[245,246] Printed electrical and electrochemical sen-
sors offer more accuracy and the possibility for connecting 
the system directly to electrical healthcare systems and deci-
sion-making. Besides physisorption being typical in optical 
sensors, immobilization onto electrodes can be attained in 
many different ways, such as through covalent binding or via 
binding affinity, or by electrochemical methods, for example, 
electropoly merization.[247,248] Metal electrodes, especially gold, 
enable fabrication of supramolecular structures based on 
layer-by-layer growth of surfactant and protein layers through 
thiol and biotin-streptavidin chemistry, for example, C-reac-
tive protein (CRP) detection of inflammation from blood.[249] 
The most advanced systems include a sensor, battery, display, 
and circuitry being printed on paper or plastics, only the logic 
component being silicon-based.[250] Such stand-alone devices 
have been used, for example, for analysis of artificial urine 
samples,[251] ATP in human serum samples,[252] as well as cho-
lesterol, lactate, and alcohol in blood and urine.[242] Thin film 
transistors (TFT) have been used for developing linear glucose 
sensors based on reduction/oxidation reactions.[253] In addition, 
paper-based electrochemical ELISA test intended for pathogen 
detection has been developed, especially for use in developing 
countries. When wireless captures of sensor data is an issue, 
radio-frequency identification (RFID) technology is consid-
ered especially attractive, enabling wireless collection of large 
amounts of data from a matrix of sensors. Such sensor systems 
have been used for health monitoring by using, for example, 
a skin sensor.[254] Also microfluidic structures can be created 
into a paper substrate, the pore network of which can be uti-
lized for transport of liquid-soluble analytes by the capillary 
action.[241,242,245,246] Modern printers equipped with a matrix of 
print heads enable simultaneous processing of different func-
tional inks, boosting the possibilities for manufacturing smart 
sensor systems, which may offer novel alternatives for preven-
tive healthcare with reduced costs.[255,256]
Patterned reaction arrays have also been constructed by 
one-step printing of a pattern of strongly hydrophobic poly-
dimethylsiloxane (PDMS) onto a coated or noncoated paper 
substrate.[239,257] Using this array, both optical and electrical 
sensors for glucose detection have been demonstrated.[239,247] 
Paper-based test platforms also enable many surface proper-
ties to be adjusted and tested under cell culture experiments. 
Recent reports show that surface topography (roughness) and 
chemistry (surface energy, polar and dispersive components) 
have an effect on cell growth.[258] Likewise, proteins intermedi-
ating cell adhesion and proliferation adhere selectively to sur-
faces of varying charge, hydrophilicity, and contact potential.[235] 
Besides these passive ways of controlling cell adhesion and 
growth, a step toward active control and stimuli can be taken by 
combining printed electrodes and fluidic operations. When fur-
thermore incorporating drugs or vitamins in the substrate bulk 
matrix, studies on dissolution rate and release kinetics become 
possible. For example, growth factor presentation for cell differ-
entiation has been steered through electrochemical control.[259] 
Graphene with its excellent electronic conductivity and optical 
transparency has been used for cell-culture studies as recently 
reviewed by Goenka et al.[260] Graphene can be made into gra-
phene oxide (GO) containing carboxylic, epoxy, and hydroxide 
groups allowing for further functionalization. The amphiphi-
licity of the GO allows for a multitude of functionalization path-
ways including both hydrophilic as well as hydrophobic drug 
molecules.[260] Dynamic control of the cell growth substrate 
using both redox-active materials for peptide release[261] and 
using potential control has been demonstrated.[262] The use of 
stimuli-responsive materials for making dynamic in cell culture 
substrates has recently been reviewed by Kim and Hayward.[263] 
GO is here an especially interesting alternative, since it allows 
for precise control of the reduction rates and thereby also the 
amount of drug release in vitro.
Furthermore, successful electrochemical experiments with 
semitransparent electrodes prepared on transparent substrates 
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is foreseen to enable combined electrochem-
ical and optical studies of different stages of 
cell culture.[264]
5. Model Systems to Decipher 
Mechanisms of Disease, for Drug 
Screening, and for the Evaluation of 
Efficacy and Safety
Advances in biological knowledge accel-
erate the discovery of the molecular basis 
of human diseases and aid in the identifica-
tion of therapeutic targets. This allows for 
the development of new therapeutics and 
diagnostics, the efficacy and safety of which 
need to be properly evaluated in appropriate 
disease models. Today, a variety of model sys-
tems exists to gain more insight into disease 
processes and for the evaluation of diagnostic 
and therapeutic approaches. These model 
systems include cells cultured in vitro, 3D 
“organoid” cultures that mimic tissue-like 
or organ-like structures and various in vivo 
animal systems (Figure 10). Recently, more 
complex engineered disease models that 
incorporate mechanical and physical cues, 
cell composition and organization, as well 
as the electrical and chemical signals of tis-
sues and organs have been developed. While 
each system has its advantage and may lead 
to important insights into cellular disease 
mechanisms and responses to therapy, each 
system also has its limitations. Simple cel-
lular systems are not physiological and lack 
the functional cross-regulation between cell 
types and organs. Animal models may fail 
to recapitulate the human response. There 
may be limitations to visualize molecular-
scale disease processes at high resolution 
in real time or to carry out biochemical and 
genetic analyses to understand how tissue–
tissue interactions contribute to the patho-
physiology and response to therapy. For an 
efficient drug discovery and development 
process and predictive evaluation of safety 
and efficacy, we need to be aware of the advantages and dis-
advantages of different model systems. Figure 11 summarizes 
the models discussed in this review and highlights the pros and 
cons of each model system.
5.1. In Vivo Models
5.1.1. Murine Models
Rodent disease models are still central and irreplaceable mam-
malian models in DDD and for preclinical in vivo studies.[265] 
Mice are the most commonly used rodents, due to the avail-
ability of many disease and transgenic models that allow for 
the discovery of new druggable pathways and for preclinical 
studies to test novel drugs, drug modulations, or diagnostics 
technologies.[266] Although only a few disease models in mice 
are identical to the human disease, drug efficacy, toxicity, and 
biodistribution of materials, material-based drugs, or diagnos-
tics tools are often similar enough to warrant testing in mice 
prior to clinical trials.[266] Mouse disease models can be chemi-
cally induced (e.g., carcinogens, compounds inducing a specific 
disease such as colitis), induced by mechanical injury to tissues 
(e.g., skin wounds, muscle damage), induced by biologically 
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agents (e.g., bacteria, virus), or genetically induced models.[266] 
Genetic models have disease phenotypes caused by overexpres-
sion of a mutation or by knockout of a gene central for the dis-
ease process. More recently, developed humanized knock-in 
models, in which the murine gene is replaced by the human 
gene, modified or unmodified, may give greater insight into the 
molecular mechanisms of the human disease. Mice engrafted 
with functional human cells or tissues are also considered as 
humanized models,[267] and mice can further be utilized as bio-
reactors for production of biopharmaceuticals.[268] Mice can, 
thus, be physiological hosts for human tumor cells, such as in 
orthotropic xenograft implants, where cultured cancer cells are 
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Figure 11. Overview of biological model systems and the advantages and disadvantages of each model.
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introduced to the mouse and the tumor growth and the effect 
of, for example, cancer nanotherapy can be easily monitored by 
measuring changes in tumor size by tumor palpitation and in 
vivo imaging of a diagnostic markers (e.g., fluorescent) loaded 
into the particles.[269] An example of this is the orthotropic 
introduction of a human breast cancer cell line to the flank of 
mice where the gamma secretase inhibitor DAPT loaded into 
functionalized mesoporous silica nanoparticles was success-
fully used to inhibit tumor growth with improved inhibition 
and tumor growth.[269,270] Genetically engineered cancer cells, 
for example, cells with a potential oncogene mutation, can also 
be combined to this technology for specific genetic disease 
analyses or to test molecular mechanism hypothesis. Using 
this technique and cells expressing high or low levels of the 
cell fate signaling molecular, Notch was shown in breast cancer 
orthotopical transplants to induce distinct mechanisms in the 
glycolytic switch.[271] This molecular finding was later used to 
develop nanoparticles formulations with surface-functionalized 
glucose moieties and loaded with Notch inhibitors, which could 
be targeted to breast cancer cells with high Notch activity and 
was shown to successfully inhibit Notch signaling and reduce 
the number of cancer stem cells.[270]
Mice are versatile to test for drug delivery systems, since 
most human delivery routes can be tested in these models, and 
since sampling of different organs as well as imaging and blood 
and urine analysis are easily doable.[269] Murine models are also 
valuable for analyses of biodistribution.[269,270,272] Interestingly, 
not only the drug carrier itself, but also the cargo, determines 
the biodistribution in mice, as shown for 19F-loaded hollow 
mesoporous silica nanoparticles accumulating in the liver[273] 
and needs to be tested and controlled for each modulation 
in vivo.
A mammalian test organism is necessary when establishing 
formulations for oral drug delivery, since the drug formulation 
has to pass and survive the harsh environment with low pH 
and digestive enzymes of the human gastrointestinal tract.[275] 
Sheltering the drug from the environment needs to be consid-
ered for material-based formulations, which provide systems 
for lower drug dosing and reduced side effects, as most of the 
drug is expected to be delivered intact only to the target tissue. 
Of interest, a useful in vitro test tube analysis for gastrointes-
tinal delivery is to determine the durability of the formulation 
and drug using simulated gastric or intestinal fluids in vitro.[274] 
Proof-of-concept studies of targeted delivery of orally distrib-
uted nanomedicines show that drug-containing particles can be 
targeted to different parts of the digestive track using different 
particle surface modifications.[274] For example, PEI and PEG-
functionalized mesoporous silica particles were superior to 
target the colonic mucosa while PEI functionalization was more 
optimal for the small intestine. In this study, functionalized 
mesoporous silica particles loaded with the gamma-secretase 
inhibitor had improved biological activity (Notch inhibition and 
cell fate switch) at lower drug concentrations compared to drug 
alone.[274]
Main challenges in animal studies are that humans and 
mice do have many differences. As an example, most murine 
genetic models for human colorectal cancer develop tumors 
in the functionally different small intestine, where they rarely 
develop in humans, and thus, more disease specific models 
are still needed.[275] With respect to drug delivery to inflamma-
tory bowel diseases such as ulcerative colitis, novel material-
based rectal formulations have shown successful facilitation 
of mucosal healing by using drugs in hydrogels to target the 
inflamed colonic mucosa[276] or thermo-sensitive polymer plat-
forms[277] in murine models of colitis. Development and use 
of in vivo diagnostic imaging modalities is essential to follow 
effects of drugs and disease progression over time, for example, 
for intestinal inflammation by optical imaging and PET[278] or 
optical imaging of cancer growth.[279] A crucial challenge in uti-
lizing nanodiagnostics if the nanoparticles carry the diagnostic 
probe is particle integrity (e.g., that the label remain attached to 
the particle during imaging). The choice of label and imaging 
modality also needs to be considered as many different options 
exist (PET, MRI, ultrasound, and optical). Importantly, the 
chosen cargo may have an influence on the particle degradation 
and biodistribution.[273]
In summary, mice are very useful preclinical model systems 
for assessing delivery options, toxicity, biodistribution, as well 
as the biological effect of the technology platform in basal con-
ditions and in disease models. Further benefits for antitumor-
ogenic drug studies are that human-derived cells, where cell 
function and signal activity can be modulated to mimic patient 
situation prior to transplantation, can be used. It is important 
to keep in mind that mice are not human hosts, for example, 
most tumor studies must be done in immunocompromised 
mice, which may not always be directly translatable to a human 
response to therapy (Figure 11), and that murine models must 
be performed under strict ethical and stringent protocols.[280]
5.1.2. Nonmammalian In Vivo Disease Models
Although mammalian models are crucial for development of 
drugs and diagnostic tools, they are expensive and require spe-
cial ethical considerations. Nonmammalian models such as the 
fruit fly Drosophila melanogaster and the zebra fish Danio rerio 
are of great value for drug development and diagnostics, as 
they provide fast, ethical, and cost-efficient platforms for initial 
testing of drug effects on target molecules, the effects on target 
cells, and the effects on target tissues in vivo. In addition, 
these models are convenient for finding conserved druggable 
target molecules, and for testing molecular markers, target 
specificity, delivery to target cells, and compound stability in 
vivo faster than in mammalian models.[281–285] Although many 
mammalian organs are missing in these lower organisms, 
several tissues are strikingly similar to their human equiva-
lents. For example, the intestinal structure and function is 
well conserved throughout evolution.[286] As many drugs are 
orally administered, lower organisms may be used to study 
uptake of small molecules in the digestive tract. To date, most 
studies with new materials in nonmammalian model organ-
isms have been focused on biosafety testing.[287,288] However, 
these models have also been used for testing, for example, the 
delivery properties of nanomaterials in vivo.[289,290] As many 
biological processes, including signaling that regulates inflam-
mation, proliferation, growth, cell death, and cell survival, are 
conserved in evolution, nonmammalian model organisms 
have been extensively used to understand the molecular and 
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genetic principles behind human disease such as malignant, 
immunological, cardiovascular, neurological, endocrine, and 
skeletal disorders. Convincingly, around 80% of the described 
human disease genes have homologues in both zebra fish 
and fruit flies.[291,292] This knowledge has been used to create 
disease model strains, which are genetically manipulated to 
mimic diseased states, such as malignant, metabolic, muscle, 
and neurological disorders.[281,292,293] Furthermore, as cellular 
processes regulating health and disease are conserved, non-
mammalian models may be useful for initial drug screening, 
as a cheap and fast model to test effects of libraries of com-
pounds on molecular modulators of disease-promoting sign-
aling pathways.
5.2. Ex Vivo and In Vitro Model Systems
5.2.1. Cell Culture and Organoids
Cells can be grown ex vivo with different levels of complexity 
for DDD applications. The most simple, often initial, and still 
mostly used biological model system is cells growing in 2D 
monolayer cultures.[294] Primary cells, immortalized or cancer 
cell lines, grow directly on plastic or on plastic coated with 
thin layers of extracellular matrix proteins (e.g., collagen, 
laminin). Traditional cell cultures are simple and rather inex-
pensive to set up in most research facilities with a cell incu-
bator and a laminar flow hood. Another benefit of a 2D cell 
culture is that a homogeneous cell population from a spe-
cific origin/tissue type (e.g., neurons, muscle, epithelia) can 
be studied. Such single cell type cultures enable testing for 
organ or cell type-specific effects such as toxicity. If the cul-
tured cells have preserved features of the physiological cell or 
organ, they are also suitable for targeting drugs to a specific 
cell type. 2D cell culture systems are also relatively easy to 
control, image, analyze, manipulate, sample, and follow over 
time. In some cases, they can be initiated to differentiate (e.g., 
muscle cells) or form barriers (e.g., colorectal Caco2 cells 
form an intestinal polarized barrier after culture in 2D for 
three weeks[295]). Importantly, human pluripotent stem cells 
can be grown in culture and can be differentiated into virtu-
ally any cell type, providing potential to elucidate molecular 
mechanisms of human diseases and help for development of 
therapies for treating diseases. Patient-specific induced pluri-
potent stem cells (iPS), where skin cells have been genetically 
reprogrammed to pluripotent stem cells, are expected to revo-
lutionize drug screening and development, provide possibili-
ties for gene therapy of genetic diseases, and solve many of 
the problems related to animal and cellular models of human 
disease.[296]
Disadvantages from 2D cell culture systems are the artifi-
cial 2D setup, and the fact that cancer cells and immortalized 
cells may function very differently compared to cells in a tissue, 
especially when approaching nontumor disease targeting. This 
is especially problematic for nontransformed epithelial cells, 
which are difficult to maintain functional in 2D culture, as they 
tend to require a 3D environment simulating the original tissue 
to grow. For example, primary hepatocytes lose their character-
istic shape and functions in a few days.[297]
To overcome the drawbacks of 2D cultures, spheroid cul-
tures, organoid or “mini-tissue” models have recently been 
developed, in which cancer cells are grown in 3D spheroids, 
or in which isolated stem cell compartments from a tissue 
are propagated in a 3D-favorable environment (e.g., matrigel) 
in organoids.[298–302] These organoids have revolutionized the 
cell culture field and brought in the crucial third dimension to 
better mimic the original tissue architecture. Since intestinal 
epithelial cells, for example, are nearly impossible to grow in 
2D cultures, small intestinal or colonic organoids can now 
be successfully grown in 3D, with the formation of typical 
features of the intestine such as a central lumen, budding of 
crypt-structures, and differentiation of stem cells to special-
ized goblet cells, enterocytes, enteroendocrine cells, and Paneth 
cells of the intestinal crypts and villi.[303] Further development 
of matrix composition, matrix patterning, and air–liquid inter-
phase systems for intestinal organoids should provide better 
in vivo mimicking systems. Organoids from many other com-
plex organs like the brain,[304] liver, and pancreas[305] have also 
been established. Kidney organoid proximal tubule cultures, 
for example, have been shown successful in predicting in 
vitro toxicity of hydroxylated generation-5 PAMAM dendrimer 
(G5-OH), when compared to murine nephrotoxic data.[306]
Disadvantages with 3D cultures are that they are compara-
tively expensive to maintain due to the cost of matrigel and 
growth and differentiation factors required in the medium. 3D 
cultures of nontransformed cells typically also grow slowly and 
organoids and spheroids require optimization for imaging[307] 
and sampling. In addition, organoids may not be the most 
suitable for studying, for example, luminal delivery options of 
drugs, since the lumen in this model is an enclosed structure 
without an in/outlet, and the delivery of nanocarriers to orga-
noids in 3D matrixes is still challenging. The following step of 
complexity is also to include other cellular components from a 
certain tissue environment, such as fibroblasts, blood vessels, 
neurons, and lymphatics (see tissue on chip Chapter 5.3.2). 
The development of biocompatible materials opens up new 
possibilities to generate material-based patterns mimicking 
in vivo conditions, enabling optimal mini-tissue modeling. 
Future diagnostics and drug design should enable personalized 
medicine applications, where patient-derived cells or organoids 
are used for defining successful drug combinations for each 
patient. These cultures may be used in combination with mate-
rial-based target drug delivery modulations and theranostics for 
successful treatment and disease monitoring.[308–310]
5.2.2. Chorion Allantoic Membrane Model for Cancer  
and Tissue Regeneration
The chorioallantoic membrane (CAM) of the developing chick 
provides a highly vascularized and immunodeficient environ-
ment, which is widely used in cancer research.[311] The model 
is suitable to monitor the growth, invasiveness, and angiogenic 
potential of tumor xenografts during approximately one week. 
Drugs targeting both cancer cell growth and neoangiogenesis 
can be analyzed subsequent to topical application, i.v. injection, 
or injection into the yolk sac, which corresponds to oral/intra-
peritoneal application. The CAM model does not violate animal 
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protection laws and is a good alternative system to avoid and 
reduce animal trials. The model can be used to perform short-
term in vivo assessment of anticancer drugs in a rapid manner 
at low cost, using small amounts of agents. The xenografts 
are grown superficially and can be easily analyzed by confocal 
fluorescence microscopy ex vivo. The model is especially suit-
able for 3D real-time imaging of cancer cell behavior, tumor 
growth and retraction, as well as responses to therapy. The 
CAM can also be used to evaluate the repair and regeneration 
of adult tissues transplanted into the CAM.[312] The model is 
also well suited to assess vascularization of regenerating tissues 
and material-based engineered tissues for regenerative medi-
cine.[313] The CAM model can thus be employed to evaluate 
drug delivery systems as well as functional materials in both 
cancer and regenerative therapies[311,313–315] and to evaluate 
the utilization of cellular and molecular probes.[316] The draw-
back of the system is that it is not human and that the chick 
embryos do not have a developed immune system during the 
experimental window. While this allows the growth of human-
derived tissues and cells, it prevents the study of the impact of 
the immune response on treatment.
5.3. Engineered Model Systems
5.3.1. Cell Imaging Assays and High-Throughput Techniques
In order to address the important factors required to obtain 
optimal responses from complex biological systems, robust and 
accurate methods are needed to test multiple parameters in par-
allel experiments. To this end, a selection of integrated image-
based techniques has been developed, collectively referred to as 
high-throughput and high-content screening (HTS and HCS). 
These techniques include methods, hardware, and software 
for sample preparation, for real-time image acquisition, and 
for subsequent analysis of imaging data. HTS and HCS plat-
forms help streamline experimental procedures and increase 
throughput for large-scale genetics, biochemical, biomedical, 
and pharmacological studies.[317]
Since the introduction of the first high-throughput imaging 
(HTI) platforms in the mid-1990s, a variety of automated com-
mercial HTI systems have been developed, for example, Array-
Scan (ThermoFisher), CellIQ (TSE spol. s r.o.), Cell Voyager 
(Yokogawa), Image Express (Molecular Devices), IN Cell Ana-
lyzer (GE Healthcare), Opera and Operetta (PerkinElmer), and 
IncuCyte (Essen Bioscience). Examples of systems with true 
HCS capacity are semiautomatic systems Nikon A1MP (Nikon), 
Zeiss Lightsheet Z.1 (Zeiss), and Leica HCS A (Leica Micro-
systems).[318] These systems have been developed and evolved 
to the extent that they are firmly established in industrial and 
academic settings for a broad spectrum of applications. True 
“walk-away” high-throughput automation is achieved when an 
inverted microscope with a long-range air objective is integrated 
with automated liquid handling systems. The core technologies 
of HCS are automated fast image acquisition modules, with 
robust data management systems combined with image anal-
ysis capabilities. Image-processing software should be robust 
enough to handle images with variable quality, remove noise, 
separate subcellular compartments, and convert image features 
such as object shape, area, intensity level, and localization into 
numerical values for quantitative analysis. The systems are to 
an increasing extent also able to incorporate multicolor fluores-
cence techniques. Additional parameters, such as pH, oxygen 
content, electrical impedance, and force, can be measured by 
integrating various biosensors in the HCS system.[319] The 
multiparametric nature of the HTS/HCS-based cellular assays 
allows monitoring cell activity such as cell cycle, cell prolif-
eration, migration, differentiation, invasion, as well as subcel-
lular morphology, organelle tracking, molecular dynamics, and 
interactions.
Drug screening requires assays, which identify compounds 
that would ideally be highly efficacious in the human disease. 
Typically, a multistage process is implemented, where assays 
of increasing complexity, that is, from molecules to cells, orga-
noids, and in vivo studies are required. Cell-based FRET assays 
can be highly advantageous as they detect events close to a 
physiological target (protein or other biomolecule) (Scheme 2).
The current challenge of HTS is to obtain sufficient image 
resolution and throughput simultaneously in cells and tissues. 
Emerging new technologies, including multiphoton micro-
scopy,[320] different forms of super-resolution imaging,[321] and 
light-sheet microscopy,[322] will become available in formats that 
are compatible with HCS. This kind of technologies will pave 
toward understanding the physiological role of molecules in the 
context of tissue functions and disease processes.[323,324] High-
throughput drug screening is one major application of these 
advancements, being able to obtain qualitative and quantitative 
data of cell and tissue responses to compounds.[318,325]
5.3.2. Engineered Wound Healing and Tissue Regeneration Models
Multiple complex epithelial cell layers and epithelial–mesen-
chymal interactions characterize the external and internal epi-
thelia. These features of native tissues are generally absent in 
the in vitro model systems that are available for wound healing 
studies.[326,327] Therefore, new injury models recapitulating 
the healing processes in, for example, skin, cornea, and liver, 
are desired tools for tissue engineering and tissue therapy 
screening. The basic building blocks of engineered wound 
healing models are cells, signals (mechanical, electrical, or 
biochemical), and scaffolding material. Both natural and syn-
thetic materials have been employed to build scaffolds for 
tissue repair. Exogenous scaffolds are able to provide structure 
to a developing tissue, allowing cells to adhere, proliferate, dif-
ferentiate, and secrete ECM in a 3D fashion.[328] Because cells 
respond differently to substrates of different scaffold stiffness 
and porosity, manipulating scaffold parameters can be a useful 
technique to control cell behavior.[192] In addition, to elicit a 
desired cellular response, growth factor-binding sequences/
domains can be incorporated within the scaffold.[329]
Novel biomaterials-based strategies are aiming to recapitu-
late structural and functional features in acute wound healing 
and also enable modeling of the pathobiology of chronic 
wounds.[330,331] For instance, cultured keratinocyte graft models 
have been used to study repair of partial-thickness wounds, 
where the major damage is to the epidermis.[332] However, cul-
tured keratinocyte systems lack a dermal component that, if 
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present, would provide greater mechanical 
stability and possibly prevent wound contrac-
tion. To mimic the full thickness of wounds 
that involve the loss of both the epidermal 
and dermal layers of the skin, a bilayered 
skin composite model has been developed, 
consisting of a collagen lattice with dermal 
fibroblasts covered with epidermal keratino-
cytes. This invention is not only used for 
basic research, but also undergoing evalu-
ation in clinical trials for the treatment of 
burns and the epidermolysis bullosa skin-
blistering disease.[333] Another innovation is 
an engineered cornea model with a multilay-
ered structure, in which accelerated wound 
healing is observed after treatment with 
epidermal growth factor (EGF) and fibrin, 
similarly as in native tissue.[334] Recently, 3D 
biofabrication techniques have been further 
developed, enabling manufacturing of con-
structing or patterning materials with a high 
degree of control to create complex material 
geometries and cellular environments resem-
bling endogenous tissues.[335] As no ideal 
wound therapy has been identified, these 
novel tissue-engineering approaches are 
showing remarkable promise for the treat-
ment of various types of chronic wounds. 
These engineered models can also be used 
for experimental applications, such as drug 
screening.
5.3.3. Disease Models on Chips
Organs-on-chips are microfluidic cell culture 
devices, which can incorporate mechanical, 
chemical, and electrical stimuli to mimic the 
physiological context.[336,337] Several different 
cell types can be cultured in these devices 
in ordered geometries, and the physical and 
chemical environment in these systems can 
be tightly controlled. The devices are well 
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Scheme 2. Design of FRET-based high-content screening assays. Cell-based FRET (fluores-
cence resonance energy transfer) assays allow detecting physiological events, such as pro-
tein interactions, conformational changes, or posttranslational modifications, directly at the 
drug target. FRET biosensors that can detect membrane anchorage of lipid-modified proteins, 
such as small GTPases (e.g., K-ras), heterotrimeric G-proteins (coupling to GPCRs), and Src-
kinases, are particularly simple to implement and interesting for both screening and target/
hit validation.[34–36] If membrane nano- or microscale membrane organization is disrupted, a 
loss of FRET is observed (A). This loss of FRET can be easily monitored at least in the medium 
throughput format using, for example, flow cytometry (B).[37,38] Automated FLIM (fluorescence 
lifetime imaging microscopy)[39] (C) and anisotropy readout on plate readers (D). A) Cell-
based FRET-assay design for lipid-anchored membrane signaling proteins (orange). FRET 
fluorophores are in blue and yellow. B) FRET readout using a fluorescence flow cytometer. 
Analysis of the FRET efficiency in dependence of the biosensor expression to derive Emax. This 
value can report about the change in membrane anchorage of two myristoylation biosensors, 
which were derived from Yes- and Src kinases, upon treatment with a myristoylation inhibitor. 
C) FLIM-FRET imaging of cells expressing a related biosensor construct mGFP-HRasG12V 
(left, donor-construct only) and together with the 
acceptor mRFP-RBD. The increase in fluorescence 
lifetime reports on the loss of FRET, due to loss 
of membrane anchorage after treatment with the 
inhibitor compactin. D) Fluorescence anisotropy/
polarization-based homo-FRET analysis requires 
only expression of one labeled species (here mGFP-
tagged Ras-NANOPS). Left: Imaging-based anisot-
ropy measurements show the increase in anisotropy, 
as the sample becomes more polarized due to the 
loss of FRET, which depolarizes. Right: Such assays 
are also easily implemented on fluorescence plate 
readers and sensitively report on changes of homo-
FRET after treatment of Ras-NANOPS expressing 
cells with compactin.
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suited for detailed studies of material–bio interactions and eval-
uation of therapeutic efficacy in a more physiological context. 
The chips can incorporate primary cell isolated from patients 
or cells differentiated from induced pluripotent cells[338,339] to 
mimic human pathophysiology. This enables the evaluation of 
individual responses to therapies. The devices can be used to 
study toxicity and therapeutic efficacy over many days. They 
are also suitable for high-resolution imaging, enabling detailed 
analysis of the interaction of nanomaterials with cells, cellular 
structures, and biological barriers. Small airway-on-chips enable 
analysis of human lung inflammation and drug responses in 
vitro,[340] and a lung-on-chip was recently developed as a human 
disease model of drug toxicity-induced pulmonary edema and 
used to identify potential new therapeutics.[341] A blood-brain-
barrier (BBB)-on-chip was used to elucidate the mechanisms 
of neuroinflammation[342] and should be a valuable tool to 
evaluate drug delivery vehicles developed to cross the BBB. The 
BBB was formed by human brain microvascular endothelial 
cells (hBMVECs) that were grown in the absence or presence of 
and human brain pericytes or primary human brain astrocytes. 
The model was used to study the contribution of astrocytes and 
pericytes to neuroinflammation but could easily be adopted to 
evaluate drug delivery over the BBB. Technologies combining 
several tissues in one device, for example, multi organ-on-chip, 
can be used to evaluate systemic and toxic responses to nano-
particles.[343] Cancer-on-chip devices are valuable tools to study 
processes of metastasis, interactions within the tumor micro-
environment,[344] as well as to evaluate efficacy of drugs and 
tumor-targeted nanotechnology. These body-on-chip devices 
are relevant in vitro models for evaluating nanoparticle inter-
actions with human tissues, as well as pharmacokinetics and 
pharmacodynamics and therapeutic efficacy of new therapeu-
tics. They can be very useful for predicting human response to 
new compounds, which has been traditionally challenging. The 
organ-on-chip technology is still an emerging field. There are 
however several engineering challenges linked to these technol-
ogies. Manufacturing is slow, expensive, and requires skills and 
special biofabrication facilities. The functionality of the tissue, 
as well as the environmental components (flow, mechanical 
movement, chemical environment) need to be constantly 
monitored.[345,346] However, with these challenges met, the 
technology can be valuable for predictive and translational dis-
coveries within the fields of drug development and diagnostics.
6. Conclusions
The introduction of novel materials technologies and mate-
rials in health applications raises new challenges. Safety, bio-
distribution, and therapeutic efficacy need to be systematically 
addressed by certified testing systems. The behavior in physio-
logical relevant contexts of each novel system needs to be tested 
for different administration routes. Equally important is to elu-
cidate the interactions of, and mechanisms behind, different 
materials with biological barriers and biomembranes, and 
the immune system. Another dimension is the effect of novel 
materials on cellular and subcellular molecular processes. Effi-
cacy assessment is often a “hit-and-run approach,” where the 
study ends when the desired effect is achieved. Few research 
efforts focus on understanding the interaction between mate-
rials and cellular and molecular processes in detail, although 
good examples of such approaches do exist.
Technological advances have led to the generation of delivery 
systems that enable multidrug delivery and controlled release. 
More rigid synthesis protocols and creative solutions to gain 
control of physicochemical parameters of the given technology 
have given rise to “smart” health care materials to meet any 
defined need. The clinical value of these advances and the 
necessary knowledge base for future development will only be 
gained through feedback from standardized testing of biological 
and physiological performance. Information on the behavior on 
a cellular level, toxicity on the nanoscale level, and interaction 
with cellular and biochemical mechanisms is equally impor-
tant. This knowledge is a necessity for the translation of novel 
materials to the clinic.
Today, there is a tremendous variability in the methods used 
to assess the applicability and performance of novel mate-
rials. These methods are often semiquantitative or indicative, 
as quantitative methods in relevant model systems are time-
consuming, require a large number of animals and high-
throughput methods, and become very expensive. Another 
problem is the lack of benchmarking to other materials and 
clinical standards. Different materials are tested in parallel 
in different research groups using different model systems. 
Hence, there is no relevant comparison between materials 
and we lack “specification sheets” for the given technology, a 
must in the pharmaceutical industry and for successful clinical 
translation. There is an urgent need to reach consensus on the 
models, methods, and biological platforms used to test medical 
applicability. A multitude of different disease models is used, 
and often the number of animals included does not allow for 
proper statistical evaluation of the significant benefit, as com-
pared to controls or standards. In many cases, the animal dis-
ease models do not mimic the human disease, which itself can 
be very individual in patients. Equally important is the devel-
opment of standardized, large-scale synthesis protocols, and 
standardized high-resolution and sensitive material characteri-
zation methods.
An interesting idea is to integrate mathematical modeling 
in the DDD process to be able to predict therapeutic efficacy 
and safety. Of note, such QSAR requires solid experimental 
data to be fed in as parameters for the prediction. Further inte-
grating high-throughput OMICs technology such as genomics, 
proteomics, metabolomics, or epigenetics will bring beneficial 
advances to the development process.
7. Outlook
This review covers several central aspects of the advancement 
of the drug development process with focus on biomaterials 
and technologies to be used in biomedical applications. Below, 
we highlight future challenges and opportunities within the 
field: 
• Integration of biological, materials science, and pharmaco-
logical processes at all levels from molecular signaling to 
animal-level physiology is important.
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• Nanoparticle- and other material-based targeted drug formu-
lations require special consideration when tested for toxicity 
in any model system, since the different components, for ex-
ample, the drug, the carrier material, the targeting molecule, 
or the diagnostic marker, may have individual or added safety 
concerns that are difficult to separate from each other.
• Structural data and the computational tools help explore 
molecular interactions and screen for potential ligands and 
novel scaffolds for drug development. Used responsibly, 
computational methods offer a way to explore the wide realm 
of possibilities and narrow down candidate hypotheses to a 
reasonable number that can then be investigated in more de-
tail.
• Design and discovery work best when tightly integrated with 
molecular synthesis and testing for binding strength and 
biological activities. The results of these cycles of synthesis, 
testing, and design feed on each other and help optimize the 
discovery of chemistries that help fulfill the requirements for 
a given target.
• Combination of nano-sensor technology, smart nanomateri-
als with nano-scaffolding systems will allow to monitor and 
precisely control specific cellular components.
• Incorporation of functionality and tailoring of composites of 
natural polymers for versatile opportunities will help meet 
the individually desired solutions for drug delivery.
• Development of new manufacturing technologies, such as 
printing and integrated quality control, will pave the way for 
more individualized dosage forms in drug delivery.
• The use of patient-derived induced pluripotent stem cells will 
enable us to generate in vitro and in vivo models of human 
disease.
• Engineered complex model systems that incorporate not only 
the diseased cells but also the diseased microenvironment in 
3D, together with the development of rapid and high-resolu-
tion readout assays (such as imaging) for evaluation of end-
points.
• New technologies for collecting and interpreting proteomic, 
genetic, and epigenetic data and biobanks, where patient 
material and medical data are stored will allow us to com-
pare the molecular fingerprint of diseased tissues in human 
versus animal model systems, as well as responses to treat-
ment.
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